

10089583 071102  
JC02 Rec'd PCT/PTO 28 MAR 2002

SI-100 INSTITUTE FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER  
11560-003US1

U.S. APPLICATION NO. (If Known, see 37 CFR 1.5)

10/089583

INTERNATIONAL APPLICATION NO.  
PCT/GB00/03758

INTERNATIONAL FILING DATE  
2 October 2000

PRIORITY DATE CLAIMED  
30 September 1999

TITLE OF INVENTION  
VACCINE

APPLICANT(S) FOR DO/EO/US

Joyce S. Plested, Michael P. Jennings, Margaret Ann J. Gidney, Andrew D. Cox, James C. Richards and E. Richard Moxon

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other documents or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

☐  
☐  
☐  
☐  
☐

**CERTIFICATE OF MAILING BY EXPRESS MAIL**

Express Mail Label No.


0294076520549

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, DC 20231

3-28-2002  
Date of Deposit

Signature

*Henry Jenkins*  
Henry Jenkins  
Typed Name of Person Signing

U.S. APPLICATION NO. (IF KNOWN) <b>10/089583</b>		INTERNATIONAL APPLICATION NO. PCT/GB00/03758		ATTORNEY'S DOCKET NUMBER 11560-003US1	
17. <input checked="" type="checkbox"/> The following fees are submitted:  <b>Basic National Fee ( 37 CFR 1.492(a)(1)-( 5) ):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... <b>\$1040</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$740</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... <b>\$710</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... <b>\$100</b>  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>				<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$0.00</b>	
Claims	Number Filed	Number Extra	Rate		
Total Claims	43 - 20 =	23	x \$18	\$414.00	
Independent Claims	7 - 3 =	4	x \$84	\$336.00	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$280	\$280.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$0.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,920.00</b>	
Processing fee of <b>\$130</b> for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f))				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,920.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,920.00</b>	
				<b>Amount to be refunded:</b>	<b>\$</b>
				<b>Charged:</b>	<b>\$</b>
a. <input checked="" type="checkbox"/> A check in the amount of \$1,920.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Timothy A. French FISH & RICHARDSON P.C. 225 Franklin Street Boston, Massachusetts 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile			 SIGNATURE		
			NAME Timothy A. French		
			REGISTRATION NUMBER 30,175		

10089583 071102

Attorney's Docket No.: 11560-003 US / FJUSP82704 #3

10/089583

PCT/PTO 11 JUL 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
PCT Appln. No.: PCT/GB00/03758  
PCT Filing Date: 2 October 2000  
Title : VACCINE

Art Unit : Unknown  
Examiner : Unknown

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Paragraph beginning at page 19, line 16 has been amended as follows:

--Figure 10a illustrates ELISA titres of antibodies to *L3 gale* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease, and Figure 10b illustrates means % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement; --

Paragraph beginning at page 55, line 7 has been amended as follows:

--We present data on three paired sera taken from infants early (acute) and later (convalescent) during culture confirmed invasive meningococcal disease (IMD) that resulted from infection with *Neisseria meningitidis* isolates of immunotypes L1, L3 (MAb b5 reactive) (patients 1 and 2) and L2 immunotype (MAb B5 non-reactive) (patient 3) (Figures 10a and 10b).

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 943803619 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202.

Date of Deposit

July 11, 2002

Signature

Hervey Jenkins

Typed or Printed Name of Person Signing Certificate

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 2

Attorney's Docket No.: 11560-003US1 / F/USP82704

The *Neisseria meningitidis* isolates for patients 1, 2, 3 were L1 (B nt pl.14), L3 (B15 p1.7) and L2 (C2a p1.5) respectively. One paired sera from patient 2 infected with a *Neisseria meningitidis* strain that was MAb B5 reactive demonstrated an increase in specific inner core LPS antibodies by ELISA between early and late infection ( $p=0.03$  not significant two-tailed paired t-test, 95% CI 0.09-90.8)) (Figure 10a). Patient 1 sera demonstrated no significant difference in the titre of antibody taken early and later during IMD but the titre of the early sample was already at a high level (Figure 10a). The lack of increase may reflect higher affinity antibody in the convalescent sample that would not be detected in this ELISA. However in both patient 1 and 2 sera there was a nearly significant increase in functional activity in the convalescent sera in an opsonophagocytosis assay with L3 wild-type strain MC58 and human peripheral polymorphonuclear cells ( $p=0.06$  two-tailed paired t-test, 95%CI 0.90-5.96) (Figure 10b) (Plested *et al.* 2000b). There was no significant increase in specific antibody titre between acute and convalescent sera taken from patient 3 infected with L2 immunotype strain (MAb B5 non-reactive) as measured by ELISA (Figure 10a). There was no significant functional activity in OP assay against L3 wild-type strain with sera taken from patient 3 early or later during IMD (Figure 10b). This demonstrates the clinical relevance of the MAb B5 epitope *in vivo* and that specific inner core LPS antibodies are functional *in vivo*.--

Paragraph beginning at page 56, line 1 has been amended as follows:

--Figure 10a. ELISA titres of antibodies to L3 *galE* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease.--

Paragraph beginning at page 56, line 3 has been amended as follows:

--Figure 10b. Mean % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement.--

In the claims:

Amend claims 4, 5, 9-14, 17, 19-22, 24-27, 35-37 and 41, as follows:



Applicant : Joyce S. Plested et al.  
 Serial No. : 10/089,583  
 Filed : March 28, 2002  
 Page : 3

Attorney's Docket No.: 11560-003US1 / F/USP82704

--4. (Amended) A vaccine according to claim 1, wherein the immunogenic component is substantially free from outer core lipopolysaccharide.--

--5. (Amended) A vaccine according to claim 1, wherein the species of the pathogenic *Neisseria* is *Neisseria meningitidis*.--


--9. (Amended) A vaccine according to claim 1, wherein the immunogenic component comprises of or consists of an epitope which is a part or all of the inner core structure of a *Neisseria* LPS, is derived from this inner core, is a synthetic version of the inner core, or is a functional equivalent thereof.--

--10. (Amended) A vaccine according to claim 1, wherein the immunogenic component is an epitope on the LPS inner core characterized by the presence of a phosphoethanolamine moiety linked to the 3-position at HepII of the inner core, or is a functional equivalent thereof.--

--11. (Amended) A vaccine according to claim 1, wherein the immunogenic component is an epitope on the LPS inner core which comprises a glucose residue at HepI.--

--12. (Amended) A vaccine according to claim 1, wherein the immunogenic component is an epitope on the LPS inner core which comprises an N-acetyl glucosamine at HepII of the inner core LPS.--

--13. (Amended) A vaccine according to claim 1, wherein the inner core LPS consists of an inner core oligosaccharide attached to lipid A, with the general formula as shown:



where R1 is a substituent at the 3-position of HepII, and is hydrogen or Glc- $\alpha$ -(1, or phosphoethanolamine; R2 is a substituent at the 6-position of HepII, and is hydrogen or

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 4

Attorney's Docket No.: 11560-003US1 / F/USP82704

phosphoethanolamine; R3 is a substituent at the 7-position of HepII, and is hydrogen or phosphoethanolamine, and R4 is acetyl or hydrogen at the 3-position, 4-position or 6-position of the GlcNAc residue, or any combination thereof; and where Glc is D-glucopyranose; Kdo is 3-deoxy-D-manno-2-octulosonic acid; Hep is L-glycero-D-manno-heptose, and GlcNAc is 2-acetamido-2-deoxy-D-glucopyranose.--

--14. (Amended) A vaccine according to claim 1, wherein the immunogenic component is reactive with the B5 antibody produced by the hybridoma deposited under accession number IDAC 260900-1.--

--17. (Amended) A vaccine according to claim 15, wherein the said few immunogenic components elicit functional antibodies in at least 85% of the strains within the species of the pathogenic *Neisseria*.--

--19. (Amended) A vaccine according to claim 15, wherein an immunogenic component is reactive with the A4 antibody produced by the hybridoma deposited under accession number IDAC 260900-2.--

--20. (Amended) A vaccine according to claim 1, wherein the immunogenic element of the vaccine is an epitope accessible on the bacterium in the presence of bacterial capsule.--

--21. (Amended) A vaccine according to claim 1, comprising one or more immunogen components which are capable of stimulating antibodies which are opsonic.--

--22. (Amended) A vaccine according to claim 1 for the treatment of *Neisseria meningitidis*.--

--24. (Amended) A vaccine according to claim 1 for the prevention of meningitis, septicaemia or pneumonia or other manifestation of systemic or local disease occasioned by *Neisseria meningitidis*.--

--25. (Amended) A vaccine according to claim 1 for the treatment of urethritis, salpingitis, cervicitis, proctitis, pharyngitis, pelvic inflammatory disease or other manifestation of systemic or local disease occasioned by *Neisseria gonorrhoeae*.--

--26. (Amended) A vaccine according to claim 1 which is a conjugated vaccine.--

--27. (Amended) A vaccine according to claim 1, which is derived from a commensal *Neisseria*.--

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 5

Attorney's Docket No.: 11560-003US1 / F/USP82704

--35. (Amended) A pharmaceutical preparation comprising an antibody according to claim 29 in combination with a pharmaceutically acceptable carrier.--

--36. (Amended) A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of a vaccine according to claim 1.--

--37. (Amended) A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of an antibody according to claim 28.--

--41. (Amended) Use of an antibody according to claim 29 in the preparation of a medicament for the treatment of *Neisseria* infection.--

In the abstract:

Please include the following abstract.

--The invention relates to a vaccine for the treatment of disease caused by *Neisseria*, the vaccine including one or more immunogenic components for *Neisseria* serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating *Neisseria* infections. The immunogens are based on elements of the inner core lipopolysaccharide.--

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 6

Attorney's Docket No.: 11560-003US1 / F/USP82704

REMARKS

Claims 1-41 are pending in this application. Claims 4, 5, 9-14, 17, 19-22, 24-27, 35-37 and 41 are amended herein to better conform with the requirements of U.S. practice. Claims 1-3, 6-8, 15, 16, 18, 23, 26-34 and 38-40 remain unchanged.


Attached is a marked-up version of the changes being made by the current amendment.

Applicants submit that this application is now in condition for allowance. Early favorable action is solicited. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: \_\_\_\_\_

*Jul 11, 2002*



\_\_\_\_\_  
Timothy A. French  
Reg. No. 30,175

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 7

Attorney's Docket No.: 11560-003US1 / F/USP82704

**Version with markings to show changes made**

**In the specification:**

Paragraph beginning at page 19, line 16 has been amended as follows:

--Figure [10] 10a illustrates ELISA titres of antibodies to *L3 galE* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease, and Figure 10b illustrates means % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement; --

Paragraph beginning at page 55, line 7 has been amended as follows:

--We present data on three paired sera taken from infants early (acute) and later (convalescent) during culture confirmed invasive meningococcal disease (IMD) that resulted from infection with *Neisseria meningitidis* isolates of immunotypes L1, L3 (MAb b5 reactive) (patients 1 and 2) and L2 immunotype (MAb B5 non-reactive) (patient 3) [(Figure 10)] (Figures 10a and 10b). The *Neisseria meningitidis* isolates for patients 1, 2, 3 were L1 (B nt pl.14), L3 (B15 p1.7) and L2 (C2a p1.5) respectively. One paired sera from patient 2 infected with a *Neisseria meningitidis* strain that was MAb B5 reactive demonstrated an increase in specific inner core LPS antibodies by ELISA between early and late infection ( $p=0.03$  not significant two-tailed paired t-test, 95% CI 0.09-90.8)) (Figure 10a). Patient 1 sera demonstrated no significant difference in the titre of antibody taken early and later during IMD but the titre of the early sample was already at a high level (Figure 10a). The lack of increase may reflect higher affinity antibody in the convalescent sample that would not be detected in this ELISA. However in both patient 1 and 2 sera there was a nearly significant increase in functional activity in the convalescent sera in an opsonophagocytosis assay with L3 wild-type strain MC58 and human peripheral polymorphonuclear cells ( $p=0.06$  two-tailed paired t-test, 95%CI 0.90-5.96) (Figure 10b) (Plested *et al.* 2000b). There was no significant increase in specific antibody titre between acute and convalescent sera taken from patient 3 infected with L2 immunotype strain (MAb B5 non-reactive) as measured by ELISA (Figure 10a). There was no significant functional activity in

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 8

Attorney's Docket No.: 11560-003US1 / F/USP82704

OP assay against L3 wild-type strain with sera taken from patient 3 early or later during IMD (Figure 10b). This demonstrates the clinical relevance of the MAb B5 epitope *in vivo* and that specific inner core LPS antibodies are functional *in vivo*.--

Paragraph beginning at page 56, line 1 has been amended as follows:

--Figure [10. A] 10a. ELISA titres of antibodies to L3 *galE* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease.--

Paragraph beginning at page 56, line 3 has been amended as follows:

--Figure 10b [B]. Mean % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement.--

In the claims:

Claims 4, 5, 9-14, 17, 19-22, 24-27, 35-37 and 41 have been amended as follows:

--4. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component is substantially free from outer core lipopolysaccharide.--

--5. (Amended) A vaccine according to [any preceding] claim 1, wherein the species of the pathogenic *Neisseria* is *Neisseria meningitidis*.--

--9. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component comprises of or consists of an epitope which is a part or all of the inner core structure of a *Neisseria* LPS, is derived from this inner core, is a synthetic version of the inner core, or is a functional equivalent thereof.--

--10. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component is an epitope on the LPS inner core [characterised] characterized by the presence of a phosphoethanolamine moiety linked to the 3-position at HepII of the inner core, or is a functional equivalent thereof.--


--11. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component is an epitope on the LPS inner core which comprises a glucose residue at HepI.--

Applicant : Joyce S. Plested et al.  
 Serial No. : 10/089,583  
 Filed : March 28, 2002  
 Page : 9

Attorney's Docket No.: 11560-003US1 / F/USP82704

--12. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component is an epitope on the LPS inner core which comprises an N-acetyl glucosamine at HepII of the inner core LPS.--

--13. (Amended) A vaccine according to [any preceding] claim 1, wherein the inner core LPS consists of an inner core oligosaccharide attached to lipid A, with the general formula as shown:



where R1 is a substituent at the 3-position of HepII, and is hydrogen or Glc- $\alpha$ -(1, or phosphoethanolamine; R2 is a substituent at the 6-position of HepII, and is hydrogen or phosphoethanolamine; R3 is a substituent at the 7-position of HepII, and is hydrogen or phosphoethanolamine, and R4 is acetyl or hydrogen at the 3-position, 4-position or 6-position of the GlcNAc residue, or any combination thereof; and where Glc is D-glucopyranose; Kdo is 3-deoxy-D-*manno*-2-octulosonic acid; Hep is L-*glycero*-D-*manno*-heptose, and GlcNAc is 2-acetamido-2-deoxy-D-glucopyranose.--

--14. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic component is reactive with the B5 antibody produced by the hybridoma deposited under accession number IDAC 260900-1.--

--17. (Amended) A vaccine according to claim 15 [or 16], wherein the said few immunogenic components elicit functional antibodies in at least 85% of the strains within the species of the pathogenic *Neisseria*.--

Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 10

Attorney's Docket No.: 11560-003US1 / F/USP82704

--19. (Amended) A vaccine according to [any of the claims] claim 15 [to 18], wherein an immunogenic component is reactive with the A4 antibody produced by the hybridoma deposited under accession number IDAC 260900-2.--

--20. (Amended) A vaccine according to [any preceding] claim 1, wherein the immunogenic element of the vaccine is an epitope accessible on the bacterium in the presence of bacterial capsule.--

--21. (Amended) A vaccine according to [any preceding] claim 1, comprising one or more immunogen components which are capable of stimulating antibodies which are opsonic.--

--22. (Amended) A vaccine according to [any preceding] claim 1 for the treatment of *Neisseria meningitidis*.--

--24. (Amended) A vaccine according to [any preceding] claim 1 for the prevention of meningitis, septicaemia or pneumonia or other manifestation of systemic or local disease occasioned by *Neisseria meningitidis*.--

--25. (Amended) A vaccine according to [any of the claims] claim 1 [to 22] for the treatment of urethritis, salpingitis, cervicitis, proctitis, pharyngitis, pelvic inflammatory disease or other manifestation of systemic or local disease occasioned by *Neisseria gonorrhoeae*.--

--26. (Amended) A vaccine according to [any preceding] claim 1 which is a conjugated vaccine.--

--27. (Amended) A vaccine according to [any preceding] claim 1, which is derived from a commensal *Neisseria*.--

--35. (Amended) A pharmaceutical preparation comprising an antibody according to [any of claims] claim 29 [to 32] in combination with a pharmaceutically acceptable carrier.--

--36. (Amended) A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of a vaccine according to [any of claims] claim 1 [to 28].--

--37. (Amended) A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of an antibody according to [any of claims] claim 28 [to 31].--

--41. (Amended) Use of an antibody according to [any of claims] claim 29 [to 32] in the preparation of a medicament for the treatment of *Neisseria* infection.--



Applicant : Joyce S. Plested et al.  
Serial No. : 10/089,583  
Filed : March 28, 2002  
Page : 11

Attorney's Docket No.: 11560-003US1 / F/USP82704

In the abstract:

--The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine [comprising] including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.--

## Vaccine

The present invention relates to vaccines against *Neisseria* infection, especially to infection by pathogenic *Neisseria meningitidis* and *Neisseria gonorrhoeae*.

### Background of the Invention

Septicaemia and meningitis caused by *Neisseria meningitidis* remain a global health problem, especially in young children. *Neisseria meningitidis* is usually a commensal of the nasopharynx, the only major natural reservoir of this organism. The virulence factors that potentiate the capacity of *Neisseria meningitidis* to cause invasive disease include capsular polysaccharides, pili (fimbriae) or outer membrane proteins and lipopolysaccharides (DeVoe, I.W. 1982. Microbiol Rev 46: 162-190, Jennings, H.J. 1989. Contrib Microbiol Immunol 10: 151-165, Tonjum, T., and M. Koomey. 1997. Gene 192: 155-163, Nassif, X., *et al.* 1997. Gene 192: 149-153, Poolman, J.T. 1996. Adv Exp Med Biol 397: 73-33, Verheul, A.F., *et al.* 1993. Microbiol Rev 57: 34-49, Preston, A., *et al.* 1996. Crit Rev Microbiol 22: 139-180).

Existing licensed vaccines against capsular serogroups A, C, W and X are available (Frasch, C.E. 1989. Clin Microbiol Rev 2 Suppl: S134-138, Herbert, M.A., *et al.* 1995. Commun Dis Reg CDR Rev 5: R130-135, Rosenstein, N., *et al.* 1998. J.A.M.A. 279: 435-439), but generally lack satisfactory immunogenicity in very young children and do not induce long lasting protective immunity (Peltola, H., *et al.* 1977. N Engl J Med 297: 686-691, Peltola, H., *et al.* 1985. Pediatrics 76: 91-96, Reingold, A.L., C.V. Broome, *et al.* 1985. Lancet II: 114-118, Lepow, M.L., *et al.* 1986. J Infect Dis 154: 1033-1036, Cadoz, M. 1998. Vaccine

16: 1391-1395). Nonetheless, their utility has been significant in affording protection to selected populations such as the military, travellers and those at exceptional risk in outbreaks or epidemics (CDC. 1990. MMWR Morb Mortal Wkly Rep 39, No. 42: 763). Very recently, meningococcal conjugate Group C vaccines have been introduced as a routine immunisation in the United Kingdom.

The major public health priority concerning invasive meningococcal infections is to identify Group B vaccines that are highly effective in infants and give long term protection. Group B strains have accounted for a substantial, often a majority of invasive *Neisseria meningitidis* infections in many countries in Europe and North America (CDR. 1997 April. Communicable Disease Weekly Report. 7, No. 14). Prevention of Group B invasive disease represents a particularly difficult challenge in vaccine development as the capsular polysaccharide is very poorly immunogenic and even conjugates have shown disappointing immunogenicity (Jennings, H.J., and H.C. Lugowski. 1981. J. Immunology 127:1011-1018). Further, there are concerns about the safety of vaccines whose rationale is to induce antibodies to the Group B polysaccharide, a homopolymer of  $\alpha$ -linked 2-8 neuraminic acid. The identical polysialic acid (PSA) is a post translational modification of a glycoprotein present on human cells, especially neurons, the latter is referred to as neural cell adhesion molecule (N-CAM) (Finne, J., *et al.* 1983. Lancet 2: 355-357). Both theoretical and experimental evidence have been used to argue that the induction of antibodies might result in auto-immune, pathological damage to host tissues.

Alternative approaches to develop vaccine candidates against Group B *Neisseria meningitidis* are being actively explored. These include: outer membrane porins (Poolman, J.T., *et al.* 1995. Meningococcal disease, p. 21-34K. Cartwright (ed.). John Wiley and sons, Wetzler, L.M. 1994. Ann N Y Acad Sci 730: 367-370, Rosenqvist, E., *et al.* 1995. Infect Immun 63:4642-4652, Zollinger, W.D., *et al.* 1997. Infect Immun 65: 1053-1060), transferrin binding proteins (Al'Aldeen, A.A., and K.A. Cartwright. 1996. J Infect 33: 153-157) and lipopolysaccharides (Verheul, A.F., *et al.* 1993. Infect Immun 61: 187-196, Jennings, H.J., *et al.* 1984. Infect Immun 43: 407-412, Jennings, H.J., *et al.* 1987. Antonie Van Leeuwenhoek

53: 519-522, Gu, X.X., and C.M. Tsai. 1993. Infect Immun 61: 1873-1880, Moxon, E.R., *et al.* 1998. Adv Exp Med Biol 435: 237-243).

The structure of *Neisseria meningitidis* LPS has been studied in considerable detail by Jennings H. and co-workers with additional contributions by others (Griffiss, J.M., *et al.* 1987. Infect Immun 55: 1792-1800, Stephens, D.S., *et al.* 1994. Infect Immun 62: 2947-2952, Apicella, M.A., *et al.* 1994. Methods Enzymol 235: 242-252, Poolman, J.T. 1990. Polysaccharides and membrane vaccines, p.57-86. In Bacterial vaccines, A. Mizrahi (ed.), *et al.* 1997. FEMS Microbiol Lett 146: 247-253). The structures of major glycoforms for several immunotypes (L1-L9) have been published L1, L6 (Di Fabio, J.L., *et al.* 1990. Can J Chem 68: 1029-1034, Wakarchuk, W.W., *et al.* 1998. Eur J Biochem 254: 626-633); L3 (Pavliak, V., *et al.* 1993. J Biol Chem 268: 14146-14152); L5 (Michon, F., *et al.* 1990. J. Biol Chem 265:7243-7247); L2 (Gamian, A., *et al.* 1992. J Biol Chem 267: 922-925); L4,L7 (Kogan, G., *et al.* 1997. Carbohydr Res 298: 191-199); L8 (Wakarchuk, W.W., *et al.*, 1996, J. Biol. Chem. 271, 19166 - 19173), L9 (Jennings, H.J., *et al.* 1983. Carbohydr. Res. 121: 233-241). Reference is also made to the following discussion of the accompanying Figure 1.

It is known that, in addition to this inter-strain variation, individual *Neisseria meningitidis* strains exhibit extensive phase variation of outer core LPS structures (reviewed in van Putten, J.P., and B.D. Robertson. 1995.Mol Microbiol 16: 847-853 and Andersen, S.R., *et al.* 1997. Microb Pathog 23: 139-155). The molecular mechanism of this intra strain variation involves hypermutable loci within the reading frames encoding several glycosyl transferases (Gotschlich, E.C. 1994. J Expt Med 180: 2181-2190, Jennings, M.P., *et al.* 1995. Mol Microbiol 18: 729-740). Similar mechanisms of phenotypic variation have been reported for other phase-variable surface components of pathogenic *Neisseria*, including Opc (Sakari, J., *et al.* 1994. Mol. Microbiol 13: 207-217), Opa (Stern, A., *et al.* 1986. Cell 47: 61-71) and PilC proteins (Jonsson, A.B., *et al.* 1991. EMBO J 10: 477-488). The high frequency, reversible molecular switching is mediated by homopolymeric tracts of cytosines or guanines through slippage-like mechanisms that results in frame shifts (Gotschlich, E.C. 1994. J Expt Med 180: 2181-2190, Jennings, M.P., *et al.* 1995. Mol Microbiol 18: 729-740, Stern, A., and T.F. Meyer. 1987. Mol. Microbiol 1: 5-12).

Furthermore, in the publication New Generation Vaccines [1997, Ed. M. M. Levine, publ. Marcel Deker Inc, New York, Chapter 34, page 481], it is stated that, with respect to vaccine development, ‘including LPS that consists only of the common inner core region of the oligosaccharide may not result in induction of bactericidal antibodies...’.

In addition, other species of the genus *Neisseria* pose global health problems. For example, *Neisseria gonorrhoeae* is involved in sexually transmitted diseases such as urethritis, salpingitis, cervicitis, proctitis and pharyngitis, and is a major cause of pelvic inflammatory disease in women.

Accordingly, there is still a need in the art for an effective vaccine against pathogenic *Neisseria* infection, such as *Neisseria meningitidis* and *Neisseria gonorrhoeae* infection.

The present invention sets out to address this need.

#### **Statement of invention**

In a first aspect, the invention relates to a vaccine for the treatment of disease caused by *Neisseria* infection, the vaccine comprising an immunogenic component of *Neisseria* strains. The vaccine presents a conserved and accessible epitope that in turn promotes a functional and protective response.

We have now discovered that the inner core of the LPS of *Neisseria* can be used to generate a protective immune response to *Neisseria* infections, for example *Neisseria meningitidis* infections. For simplicity the present invention is herein exemplified principally by discussion of vaccines and treatments against *Neisseria meningitidis* infections, but the invention extends to diseases caused by other pathogenic *Neisseria* species.

Using a range of novel monoclonal antibodies, epitopes belonging to the inner core of *Neisseria meningitidis* have been identified which have been found to be accessible to the immune system, and which are capable of stimulating the production of functional, protective antibodies. Moreover, analysis of *Neisseria meningitidis* strains using the new antibody tools indicates that certain epitopes are common to a range of *Neisseria meningitidis* disease isolates, and sometimes occur in a majority of such strains. Accordingly a vaccine comprising only a limited range of *Neisseria meningitidis* inner core epitopes can provide

effective immunoprophylaxis against the complete range of strains causing *Neisseria meningitidis* infection. Similar considerations apply to other pathogenic species.

In a related aspect, the invention provides a vaccine effective against strains of the bacteria of the genus *Neisseria*, especially strains of the species *Neisseria meningitidis*. Particularly in the latter instance, the vaccine comprises one or more immunogens which can generate antibodies that recognise epitopes in encapsulated strains. The one or more immunogens represent one or more accessible inner core epitopes. Thus, the immunogens can give rise to antibodies that recognise a majority of strains.


We use the word "principal" to refer to a majority. Thus, a principal immunogenic component elicits antibodies to a majority of strains.

In our approach, antibodies were generated by immunising mice using *Neisseria meningitidis* *galE* mutants. The antibodies produced were specific to the LPS inner core because *galE* mutants lack outer core structures. The reactivity of these antibodies against a panel of *Neisseria meningitidis* strains representative of the diversity found in natural populations of disease isolates was investigated. One monoclonal antibody reacted with 70 % of all *Neisseria meningitidis* strains tested, suggesting strong conservation of the inner core epitope recognised by this antibody, termed antibody B5. The epitope against which B5 reacts has been characterised and can be used to form the basis of a vaccine to prevent *Neisseria* infections.

A hybridoma producing the monoclonal antibody B5, designated hybridoma NmL3B5, has been deposited under the Budapest Treaty on 26 September 2000 with the International Depositary Authority of Canada in Winnipeg, Canada, and given the Accession Number IDAC 260900-1.

In this way, we have obtained proof in principle that one or more of the inner core epitopes of LPS are conserved and accessible to antibodies, that a specific immune response to these epitopes can mediate protection, and that LPS inner core oligosaccharides can be candidate

vaccines. The inner core LPS typically consists of an inner core oligosaccharide attached to lipid A, with the general formula as shown:



where R1 is a substituent at the 3-position of HepII, and is hydrogen or Glc- $\alpha$ -(1, or phosphoethanolamine; R2 is a substituent at the 6-position of HepII, and is hydrogen or phosphoethanolamine; R3 is a substituent at the 7-position of HepII, and is hydrogen or phosphoethanolamine, and R4 is acetyl or hydrogen at the 3-position, 4-position or 6-position of the GlcNAc residue, or any combination thereof; and where Glc is D-glucopyranose; Kdo is 3-deoxy-D-manno-2-octulosonic acid; Hep is L-glycero-D-manno-heptose, and GlcNAc is 2-acetamido-2-deoxy-D-glucopyranose.

### General Description of the Invention

The principal immunogenic component for *Neisseria meningitidis* strains is preferably a single immunogenic component found in at least 50 % of *Neisseria meningitidis* strains, i.e. in the majority of naturally occurring *Neisseria meningitidis* strains. The principal immunogenic component forms a candidate vaccine immunogen. Preferably the immunogenic component of the vaccine of the present invention is any one element or structure of *Neisseria meningitidis* or other species of *Neisseria* capable of provoking an immune response, either alone or in combination with another agent such as a carrier. Preferably the principal immunogenic component comprises of or consists of an epitope which is a part or all of the inner core structure of the *Neisseria meningitidis* LPS. The immunogenic component may also be derived from this inner core, be a synthetic version of the inner core, or be a functional equivalent thereof such as a peptide mimic. The inner core



LPS structure of *Neisseria meningitidis* is generally defined as that shown in Fig 1 and as outlined in the figure legend. The immunogenic component is suitably one which elicits an immune response in the presence and in the absence of outer core LPS.

The principal immunogenic component is conserved in at least 50% of *Neisseria* strains within the species, preferably at least 60%, and more preferably at least 70%. Reactivity with 100% strains is an idealised target, and so the immunogenic component typically recognises at most 95 %, or 85 % of the strains. Conservation is suitably assessed functionally, in terms of antibody cross-reactivity. We prefer that the immunogenic component is present in at least 50 % of serogroup B strains, preferably at least 60%, more preferably at least 70%, even more preferably at least 76%. Suitably, assessment of the cross reactivity of the immunogenic component is made using a representative collection of strains, such those outlined in Maiden [Maiden M.C.J., *et al.*, 1998, P.N.A.S.95, 3140 - 3145].

Preferably the principal immunogenic component is found in the *Neisseria meningitidis* immunotype L3, and preferably it is not in L2. More specifically, we prefer that the immunogen is found in the immunotypes L1, L3, L7, L8 and L9, but not in L2, L4, L5 or L6. In other words, we prefer that the immunogen, notably the principal immunogenic component, generates antibodies which are reactive with at least the L3 immunotype, and usually the L1, L3, L7, L8 and L9 immunotypes, but not with L2, and usually not the L2, L4, L5 and L6 immunotypes. There are conformational differences forced on the inner core of the L2 and L3 immunotypes by different arrangements at HepII, namely the P<sub>ETn</sub> moiety at the 6-position in L2 or at the 3-position in L3, and the Glc residue at the 3-position in L2. Currently we do not envisage the possibility of a single epitope for both L2 and L3 immunotypes. In other words, without dismissing the possibility of a single epitope, the present invention is expected to require different immunogens to elicit antibodies for L2 and L3.

Preferably the principal immunogenic component is a conserved epitope on the LPS inner core recognised by an antibody termed B5 herein. The preferred epitope of the invention is thus any epitope recognised by the B5 antibody.

Preferably the immunogenic component is a conserved epitope on the LPS inner core defined by the presence of a phosphoethanolamine moiety (PEtn) linked to the 3-position of HepII, the  $\beta$ -chain heptose, of the inner core, or is a functional equivalent thereof. In this respect, where the context permits, HepI and HepII refer to the heptose residues of the inner core oligosaccharide which respectively are proximal and distal to the lipid A moiety of the neisserial LPS, without being necessarily tied to the general formula given above.

Preferably this epitope comprises a glucose residue on HepI, the  $\alpha$ -chain heptose residue. While this glucose is not necessary for B5 binding, it is required for optimal recognition.

The principal immunogenic component of the present invention is preferably an epitope on the LPS inner core which comprises an N-acetyl glucosamine on HepII. The presence of N-acetyl glucosamine is required for optimal recognition by B5.

Preferably the principal immunogenic component comprises both the N-acetyl glucosamine on HepII and a glucose residue on HepI.

The immunogenic component of the present invention is typically only limited by the requirement for a phosphoethanolamine moiety (PEtn) linked to the 3-position of HepII of the inner core, which is required for B5 reactivity. The structure of the inner core may be modified, replaced, or removed, as necessary, to the extent that these are not needed. Similarly, any outer core structures may be modified or deleted, to the extent that structural elements are not needed. There is no requirement for the immunogenic component to lack the outer core portion, or equivalent, of the LPS. The immunogenic component may comprise outer core elements having a galactose component, for example the terminal galactose residue of the lacto-N-neotetraose. In one suitably embodiment, the immunogenic component is derived from LPS and is free from other cellular material. Alternatively, cellular material may be present, and can take the form of live or killed bacteria.

In a related aspect, the vaccine of this invention has an immunogenic epitope recognised by an antibody to a *galE* mutant of *Neisseria meningitidis*.

The B5 antibody of the present invention also recognises the inner core structures of *Neisseria gonorrhoeae* and *Neisseria lactamica*. As such, the invention extends to any *Neisseria* species, and any reference to *Neisseria meningitidis* can as appropriate be extended to other *Neisseria* species, preferably *Neisseria meningitidis*, *Neisseria gonorrhoeae* and *Neisseria lactamica*, most preferably *Neisseria meningitidis*. The invention also extends to immunogenic components in other *Neisseria* species which are related to those identified in

*Neisseria meningitidis*, either by function, antibody reactivity or structure. The invention is not limited to pathogenic strains of *Neisseria*. The vaccine of this invention can be derived from a commensal strain of *Neisseria*, especially a strain of *Neisseria lactamica*. The species *Neisseria lactamica* is typically strongly immunogenic, and therefore we prefer that the LPS inner core immunogenic component is derived from this species.

The vaccine may thus be homologous or heterologous, and thus founded on an immunogenic component from the target micro-organism, homologous, or from a different micro-organism, heterologous. The micro-organism can be naturally occurring or not, such as can be produced by recombinant techniques. In particular, the micro-organism can be engineered to modify the epitope or to modify other components.

In a further aspect of the invention we have determined that a second monoclonal antibody, herein termed A4, is able to react with inner core epitopes of nearly all of the *Neisseria meningitidis* strains which do not react with the B5 antibody. Thus, of the 100 *Neisseria meningitidis* strains tested, 30% were not reactive with B5 and were found to lack a PETn moiety at the 3-position of HepII. Of these 30 strains, 27 were reactive with A4. Accordingly, a vaccine comprising only 2 inner core epitopes, corresponding to those epitopes defined by cross reactivity with A4 and B5, provides 97% coverage of a representative collection of *Neisseria meningitidis* strains, preferably as assessed by using the collection of strains as outlined in Maiden *et al.*[*supra*]. A preferred epitope of the invention is thus also any epitope recognised by the A4 antibody.

A hybridoma producing the monoclonal antibody A4, designated hybridoma NmL4galEA4, has been deposited under the Budapest Treaty on 26 September 2000 with the International Depositary Authority of Canada in Winnipeg, Canada, and given the Accession Number IDAC 260900-2.

The present invention thus also relates to a vaccine comprising a few immunogenic components, wherein at least 70% of *Neisseria meningitidis* strains of the species possess at least one of the immunogenic components, preferably 80%, preferably 90%, and most



infection. Antibodies given directly to a patient for treatment, also are thus able to directly access the target *Neisseria* strains.

Preferably the vaccine of the present invention comprises epitopes which are capable of stimulating antibodies which are opsonic. We further prefer that these antibodies are capable of binding to wild type *Neisseria* strains to confer protection against infection and which are bactericidal.

The present invention also provides a method for treating pathogenic *Neisseria*. The method employs one or a few immunogenic components which give rise to effective antibodies, and which rely on an inner core epitope for stimulating the immune response. The immune response is ordinarily B cell mediated, but we can include T cell mediated immunity. The antibodies generated by the vaccine of this invention bind to inner core elements of the pathogenic target bacterium.

Diseases caused by *Neisseria meningitidis* include principally meningitis, septicaemia and pneumonia, and the prevention and treatment of these diseases is especially preferred in the present invention. Diseases caused by *Neisseria gonorrhoeae* include sexually transmitted diseases such as urethritis, cervicitis, proctitis pharyngitis, salpingitis, epididymitis and bacteremia/arthritis. Additionally, the invention extends to treatment and prevention of any other disease which results from *Neisseria* infection, especially to diseases in which *Neisseria* infection could weaken the immune system such that another disease or pathogen could be harmful to an individual. The treatment can be preventative or curative.

The vaccine of the present invention is a formulation suitable for safe delivery to a subject, allowing the subject to develop an immune response to future infection by *Neisseria*. Vaccines of the present invention are preferably formulated vaccines in which any of the immunogenic components of the vaccine may be conjugated, and any suitable agent for conjugation may be used. Conjugation enables modification of the presentation of the antigen, and may be achieved by conventional techniques. Examples of agents for conjugation include proteins from homologous or heterologous species. In this way, the



composition, or be provided as a separate composition for administration at the same time or a different time.

In addition to the antibodies themselves, the invention also relates to the hybridomas which produce such antibodies.

Antibodies against the immunogenic components of the invention may be generated by administering the immunogenic components to an animal, preferably a non-human animal, using standard protocols. For the preparation of monoclonal antibodies, any suitable techniques can be used. Techniques for the production of single chain antibodies (US 4,946,778) can be adapted to produce appropriate single chain antibodies. Moreover, transgenic mice or other organisms or animal may be used to express humanised antibodies immunospecific to the immunogenic components of the invention.

Alternatively, other methods, for example phage display technology may be used to select antibody genes for proteins with binding activities towards immunogenic components of the present invention.

Antibodies of the invention may be either monoclonal or polyclonal antibodies, as appropriate.

The present invention also relates to a method for the prevention of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of a vaccine as described above.

Preferably the administration is adequate to produce a long lasting antibody and/or T cell immune response to protect the subject from infection, particularly *Neisseria meningitidis* infection.

The invention also relates to a method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of an



antibody to the *Neisseria meningitidis* inner core. Preferably, the antibody is B5 or A4, or an antibody which recognises the same epitope as B5 or A4, or an antibody derived from the concepts and methodologies herein described, or is a combination thereof.

Moreover, the methods of the invention may be extended to identification of epitopes in any bacterial strain. Epitopes so identified may be tested both for accessibility, conservation across the population and functional activity, using methods as outlined in the attached Examples. The present invention thus additionally relates to a method for the identification of an immunogenic element, comprising raising an antibody to a bacterial structure, preferably a bacterial LPS structure, more preferably a bacterial inner core LPS structure, and testing the epitope recognised by the antibody for accessibility to antibody in the wild type strain, optionally also comprising testing the epitope for conservation across the bacterial population and testing for functional activity to the epitope *in vivo*.

Preferably the bacterial species are *Neisseria* species, preferably *Neisseria meningitidis*, *Neisseria gonorrhoeae* or *Neisseria lactamica*.

Specifically, the present invention provides a method to generate antibodies to the inner core of *Neisseria meningitidis*. For the first time it has been possible to screen a population of *Neisseria meningitidis* strains to identify whole population features which are independent of immunotype.

Accordingly, the present invention also relates to a method for the identification of immunogenic epitopes of *Neisseria meningitidis*, the method comprising the steps of:

- 1 generating antibodies to the inner core of *Neisseria meningitidis*, by inoculation of a host organism with a *galE* mutant strain of *Neisseria meningitidis*, and
- 2 testing such antibodies against a wild type *Neisseria meningitidis* strain to identify those antibodies which are reactive, and for which the epitopes are therefore accessible.

The potential utility of epitopes so identified may be further assessed by screening antibodies which react with the inner core of *Neisseria meningitidis galE* strain against a panel of strains which are representative of strain diversity. Preferably the strain panel is selected using an approach based upon a population analysis. Epitopes so identified may then be tested in functional assays, as outlined in Example 3.

In particular the invention extends to a method for the analysis of antibody binding to bacteria, wherein natural isolates of bacteria are studied when grown on and adherent to tissue cultured cells, such as HUVECs. This assay provides a monolayer of cells to which the bacteria adhere in a biologically relevant environment. Previous attempts using *Neisseria*, for example, directly adherent to gelatin- or matrigel-coated coverslips resulted in low numbers of adherent bacteria after repeated washings and high non-specific background staining. In particular we prefer that the antibody binding is analysed using confocal microscopy.

This method also identifies antibodies suitable for therapeutic use, and the invention extends to such antibodies.

Moreover, key biosynthetic genes for each step in LPS synthesis have been identified (Preston *et al.*, 1996, Crit. Rev. Microbiol. 22, 139 - 180) and this allows the construction of a series of mutants from which LPS glycoforms of varying size and complexities can be made available to facilitate the identification of conserved epitopes (van der Ley *et al.*, 1997, FEMS Microbiol. Letter 146, 247 - 253, Jennings *et al.* 1993, Mol. Microbiol. 10 361 - 369, Jennings *et al.*, 1995, Microb Pathog 19, 391 - 407, van der Ley *et al.*, 1996, Mol Microbiol 19, 1117 - 1125).

The present invention also relates to the gene found in *Neisseria meningitidis* which is involved in PETn substitution at the 3- position on HepII, and to genes related in structure and function. As yet no genes have been identified in any bacteria that are involved in addition of PETn to LPS structures. Using B5, specific for an inner core LPS epitope containing a PETn, we have identified a putative LPS phosphoethanolamine transferase gene (designated *hypo3*) in *Neisseria meningitidis*. *Hypo3* was named arbitrarily by us, as it is the 3rd reading frame

in a fragment of DNA selected by experimentation, from the MC58 genome sequence. The original *hypo3* is therefore from MC58. This ORF is called NMB2010 in the TIGR data base (MC58 genome sequence) and although designated as a protein of unknown function, they classify it as a "YhbX/YhjW/YijP/YjdB family protein". This indicates that homologues have been inferred in other organisms but they do not know the function of them. The homologue in the serogroup A sequence at the Sanger Centre is designated NMA0431, although this gene is smaller than *hypo3*. *Hypo3* is involved in PEtn substitution at the 3-position at HepII. Furthermore, the presence of the complete gene is required for the expression of the B5 reactive phenotype in *Neisseria meningitidis* as well as other pathogenic and commensal *Neisseria* species.

The identification of the gene allows mutants to be created which are isogenic apart from *hypo3*, and which differ only in the presence or absence of PEtn at the 3-position of HepII in the LPS inner core. Such strains can be used in comparative studies. Moreover, strains appropriate for vaccine production can be engineered so that they comprise the preferred PEtn structure at the 3-position, or engineered so that this PEtn cannot be present.

Accordingly, the invention relates to use of the *hypo3* gene, or homologue thereof, in the production of an *Neisseria* strain for the assessment, treatment or prevention of *Neisseria* infection. The homologue may have 60%, 70%, 80%, 90% or more homology or identity to *hypo3*, as assessed at the DNA level. Use of the gene includes the methods outlined above, for preparing genetically modified strains for vaccination, isolation of appropriate epitopes and generation of strains for comparative studies. More generally, we envisage the identification and use of any gene which plays a role in the biosynthetic pathway, and which has an effect on the conservation, accessibility or function of the immunogen.

The present invention is now illustrated by the following Figures and Examples which are not limiting upon the present invention, wherein:

Figure 1 illustrates the LPS structure of various *Neisseria meningitidis* immunotypes;

Figure 2 illustrates cross reactivity of B5 with selected immunotypes and mutants of *Neisseria meningitidis* LPS;

Figure 3 illustrates molecular models of the calculated (MMC) lowest energy states of the core oligosaccharide from *galE* mutants of L3, L4 and L8 dephosphorylated;

Figure 4 illustrates cross reactivity of B5 with genetically modified L3 LPS and chemically modified L8 LPS from *Neisseria meningitidis*;

Figure 5 illustrates confocal immunofluorescence microscopy of *Neisseria meningitidis* organisms strain MC58 adherent to HUVECs;

Figure 6 illustrates silver stained tricine gels of LPS preparations from *Neisseria meningitidis* group B strains not reactive with B5;

Figure 7 illustrates accessibility of the LPS epitope to A4 in *Neisseria meningitidis* whole cells;

Figure 8 illustrates conservation of the LPS epitope across *Neisseria meningitidis* serogroups;

Figure 9 illustrates the strategy for the Example 2;

Figure 10 illustrates ELISA titres of antibodies to L3 *galE* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease, and mean % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement;

Figure 11a illustrates mean % phagocytosis of *Neisseria meningitidis* MC58 with MA b B5 pre-incubated with increasing concentrations of either (i) B5 reactive or (ii) B5 non-reactive *galE* LPS with human peripheral blood polymorphonuclear cells and human complement;

Figure 11b illustrates mean % phagocytosis of pair of *Neisseria meningitidis* wild-type isogenic strains (*Neisseria meningitidis* BZ157) that are either MAb B5 reactive or B5 non-reactive with MAb B5 as the opsonin with human peripheral blood mononuclear cells and human complement;

Figure 11c illustrates mean % phagocytosis of fluorescent latex beads coated with either purified LPS from L3 *galE* mutant (10µg/ml) or uncoated, in the presence of MAb B5 or final buffer, with human peripheral blood mononuclear cells and human complement;

Figure 12 illustrates mean % survival of *Neisseria meningitidis galE* mutant in the presence and absence of MAb B5 against two-fold serial dilutions of human pooled serum starting at 40% as detected using a serum bactericidal assay;

Figure 13 illustrates Geometric mean bacteremia in the blood of groups of 5 day old infant rats 24h post-infection with  $1 \times 10^8$  cfu/ml *galE* mutant given simultaneously with: (i) no antibody; (ii) MAb B5 (10µg dose); (iii) MAb B5 (100µg dose); or (iv) MAb 735, a positive control anti-capsular antibody (2µg dose);

Figure 14 illustrates a Western blot showing purified LPS from *Neisseria meningitidis* MC58 and *galE* mutant probed with MAb B5 (ascites fluid 1:2000) detected using anti-mouse IgG alkaline phosphatase and BCIP/NBT substrate; and

Figure 15 illustrates a FACS profile comparing surface labelling of live *Neisseria meningitidis* MC58 and *galE* mutant ( $5 \times 10^8$  org./ml) with MAb B5 (culture supernatant 1:50) detected using anti-mouse IgG (FITC labelled).

## Examples of the Invention

### Example 1 Identification of immunogenic epitopes in *Neisseria meningitidis*

## Introduction

We investigated the conservation and antibody accessibility of inner core epitopes of *Neisseria meningitidis* lipopolysaccharide (LPS) because of their potential as vaccine candidates. An IgG3 murine monoclonal antibody (MAb), designated MAb B5, was obtained by immunising mice with a *galE* mutant of *Neisseria meningitidis* H44/76 (B.15.P.1.7.16 immunotype L3). We have shown that MAb B5 can bind to the core LPS of wild-type encapsulated MC58 (B.15.P.1.7.16 immunotype L3) organisms *in vitro* and *ex-vivo*. An inner core structure recognised by MAb B5 is conserved and accessible in 26/34 (76%) of Group B and 78/112 (70%) of Groups A,C,W,X,Y and Z strains. *Neisseria meningitidis* strains which possess this epitope are immunotypes in which phosphoethanolamine (PEtn) is linked to the 3-position of the  $\beta$ -chain heptose (HepII) of the inner core. In contrast, *Neisseria meningitidis* strains lacking reactivity with MAb B5 have an alternative core structure in which PEtn is linked to an exocyclic position (i.e. position 6 or 7) of HepII (immunotypes L2, L4 and L6) or is absent (immunotype L5). We conclude that MAb B5 defines one or more of the major inner core glycoforms of *Neisseria meningitidis* LPS.

These findings encourage the possibility that immunogens capable of eliciting functional antibodies specific to inner core structures could be the basis of a vaccine against invasive infections caused by *Neisseria meningitidis*.

In summary, we report that a monoclonal antibody, designated B5, has identified a cross-reacting epitope on the LPS of the majority of naturally occurring, but genetically diverse strains of *Neisseria meningitidis*. Critical to the epitope of strains recognised by the monoclonal antibody B5 is a phosphoethanolamine (PEtn) on the 3-position of the  $\beta$ -chain heptose (HepII) (Figure 1). In contrast, all *Neisseria meningitidis* strains lacking reactivity with MAb B5 are immunotypes characterised by the absence of PEtn substitution or by PEtn substitution at an exocyclic position (i.e. position 6 or 7) of HepII (Figure 1). Thus, a limited repertoire of inner core LPS variants is found among natural isolates of *Neisseria meningitidis*.

strains and these findings encourage the possibility that a vaccine might be developed containing a few glycoforms representative of all natural *Neisseria meningitidis* strains.

## Materials and Methods

### Bacterial strains

The *Neisseria meningitidis* strains MC58 and H44/76 (both B:15:P1.7.16 immunotype L3) have been described previously (Virji, M., H. Kayhty, D.J.P. Ferguson, J.E. Heckels, and E.R. Moxon, 1991. Mol Microbiol 5: 1831-1841, Holten, E. 1979. J Clin Microbiol 9: 186-188). Derivatives of MC58 and H44/76 with defined alterations in LPS were obtained by inactivating the genes, *galE* (Jennings, M.P., P. van der Ley, K.E. Wilks, D.J. Maskell, J.T. Poolman, and E.R. Moxon. 1993. Mol Microbiol 10: 361-369), *lsi* (Jennings, M.P., M. Bisercic, K.L. Dunn, M. Virji, A. Martin, K.E. Wilks, J.C. Richards, and E.R. Moxon. 1995. Microb Pathog 19: 391-407), *lgtA*, *lgtB* (Jennings, M.P., D.W Hood, I.R. Peak, M. Virji, and E.R. Moxon. 1995. Mol Microbiol 18: 729-740) *rfaC* (Stoiljkovic, I., V. Hwa, J. Larson, L. Lin, M. So, and X. Nassif. 1997. FEMS Microbiol Lett 151: 41-49), *icsA* and *icsB* (van der Ley, P., M. Kramer, A. Martin, J.C. Richards, and J.T. Poolman, 1997. FEMS Microbiol Lett 146: 247-253) (Table 1). Other wild type *Neisseria meningitidis* strains used in the study were from three collections: 1) representatives of immunotypes L1-L12 (Poolman, J.T., C.T.P. Hopman, and H.C. Zanen. 1982. FEMS Microbiol Lett 13: 339-348); 2) global collection of 34 representative *Neisseria meningitidis* Group B strains (Seiler, A., R. Reinhardt, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19: 841-856); 3) global collection of 100 strains from 107 representative *Neisseria meningitidis* strains of all major serogroups (A, B, C, W, X,Y, Z) (Maiden, M.C.J., J.A. Bygraves, E. Feil, G. Morelli, J.E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D.A. Caugant, I.M. Feavers, M. Achtman, and G.B. Spratt. 1998. PNAS 95: 3140-3145).

Capsule deficient and *galE* mutants were constructed in six *Neisseria meningitidis* Group B strains obtained from the collection as described in (Seiler, A., *et al.*, 1996. Mol Microbiol 19: 841-856) (Table 1). Other related *Neisseria* strains studied included 10 strains of *Neisseria gonorrhoeae* and commensal strains *lactamica* (8 strains), *polysaccharea* (1 strain),

*mucosa* (1 strain), *cinerea* (1 strain), *elongata* (1 strain), *sicca* (1 strain) and *subflava* (1 strain). Other Gram negative organisms included: *Haemophilus influenzae* type b (7 strains), *Haemophilus somnus* (1 strain), non-typable *Haemophilus influenzae* (8 strains), *Escherichia coli* (1 strain) and *Salmonella typhimurium* (1 strain) and its isogenic LPS mutants (*rfaC*, *rfaP*, *rfaI*) (Table 1).

#### **Bacterial culture in vitro**

All strains were grown overnight at 37°C on standard BHI medium base (Oxoid) in an atmosphere of 5% CO<sub>2</sub>.

#### **Bacterial culture in vivo using the Chick Embryo Model**

To determine the accessibility of inner core epitopes of *Neisseria meningitidis* grown *in vivo* the chick embryo model was used (Buddingh, G.J., and A. Polk. 1937. Science 86: 20-21, Buddingh, G.J., and A. Polk. 1939. J Exp Med 70: 485-498, Schrotten, H., M. Deadman, and E.R. Moxon. 1995. Pediatr. Grenzgeb. 34: 319-324). The method was modified using an inoculum of 10<sup>4</sup> and 10<sup>5</sup> *Neisseria meningitidis* organisms in a final volume of 0.1ml, to infect the chorio-allantoic fluid of 10 day old Pure Sussex chick eggs (obtained from the Poultry Unit, Institute of Animal Health, Compton, Berks). After overnight incubation (37°C) the allantoic fluid (approx. 3-5mls) was removed from the eggs and the bacteria recovered after centrifugation at 350 x g for 15 minutes. The organisms were washed in sterile phosphate buffered saline (PBS) and stored in Greaves solution (5% BSA, 5% Sodium Glutamate, 10% Glycerol) at -70°C.

#### **LPS extraction**

LPS samples were obtained from an overnight growth of *Neisseria meningitidis* plated on 5 BHI plates from which the organisms were scraped and suspended in 30 ml 0.05% phenol in PBS and incubated at room temperature for 30 minutes. Alternatively, batch cultures were prepared in fermenters using bacteria from an overnight growth (6 plates) in 50ml Difco Bacto Todd Hewitt broth (Difco) to inoculate 2.5L of the same medium. For insertion mutant strains, the medium contained 50µg/ml kanamycin. Following incubation at 37°C for 6-8h the culture was inoculated into 60L of Bacto Todd Hewitt broth in a New Brunswick



Scientific 1F-75 fermenter. After overnight growth (17h at 37°C), the culture was killed by addition of phenol (1%), and chilled to 15°C and the bacteria were harvested by centrifugation (13,000g for 20min) (Wakarchuk, W., *et al.*, 1996. J Biol. Chem. 271: 19166-19173). In either case, the crude LPS was extracted from the bacterial pellet using the standard hot phenol-water method (Westphal, O., and J. K. Jann. 1965. Meth. Carbohydr. Chem. 5:83-91) and purified from the aqueous phase by repeated ultracentrifugation (105,000 x g, 4°C, 2 x 5h) (Masoud, H., E.R. Moxon, A. Martin, D. Krajcarski, and J.C. Richards. 1997. Biochemistry 36: 2091-2103).

### Tricine gels

Equivalent amounts of whole-cell lysates of *Neisseria meningitidis* strains or purified LPS were boiled in dissociation buffer and separated on standard tricine gels (30mA for 18h) (Lesse, A.J., A.A. Campagnari, W.E. Bittner, and M.A. Apicella. 1990. J Immunol Methods 126: 109-117). Gels were fixed and silver-stained as per manufacturers instructions (BioRad). To determine the presence of sialic acid, whole cell lysates were incubated with 2.5µl neuraminidase at 37°C for 18-20h (4U/ml Boehringer 1585886) and then with 5µl proteinase K at 60°C for 2-3h to remove proteins (Boehringer 1373196) prior to separation on tricine gels (16.5%).

### Characterization of LPS from MAb B5 negative strains

LPS from wild-type and *galE*, *cap*- mutant MAb B5 negative strains were O-deacylated with anhydrous hydrazine as described previously (Masoud, H., E.R. Moxon, A. Martin, D. Krajcarski, and J.C. Richards. 1997. Biochemistry 36: 2091-2103). O-deacylated LPS were analysed by electrospray mass spectrometry (ES-MS) in the negative ion mode on a VG Quattro (Fisons Instruments) or API 300 (Perkin-Elmer/Sciex) triple quadrupole mass spectrometer. Samples were dissolved in water which was diluted by 50% with acetonitrile : water : methanol : 1% ammonia (4:4:1:1) and the mixture was enhanced by direct infusion at 4µl/min. Deacylated and dephosphorylated LPS (L8 odA HF) was prepared according to the following procedure. LPS (160mg) was treated with anhydrous hydrazine (15ml) with stirring at 37°C for 30 minutes. The reaction was cooled (0°C), cold acetone (-70°C, 50ml) was added gradually to destroy excess hydrazine, and precipitated O-deacylated LPS (L8 odA)

was obtained by centrifugation. L8 odA was washed twice with cold acetone, and redissolved in water and lyophilised. The structure of L8 odA was confirmed by negative ion ES-MS before proceeding to dephosphorylation. L8 odA was dephosphorylated by treatment with 48% aqueous hydrogen fluoride (10ml) at 0°C for 48h. The product was dialysed against water, and the O-deacylated, dephosphorylated LPS sample (L8 odA HF) was lyophilised (50mg). Loss of phosphate was confirmed by ES-MS.

### **Molecular modelling**

Molecular modelling of LPS epitopes was carried out as described previously by Brisson, J.R., S. Uhrinova, R.J. Woods, M. van der Zwan, H.C. Jarrell, L.C. Paoletti, D.L. Kasper, and H. Jennings. 1997. *Biochemistry* 36: 3278-3292). The starting geometry for all sugars was submitted to a complete refinement of bond lengths, valence and torsion angles by using the molecular mechanics program MM3(92) (QPCE). All calculations were performed using the minimised co-ordinates for the methyl glycoside. The phosphorus groups were generated from standard co-ordinates (Alchemy, Tripos software) and minimum energy conformations found in crystal structures. Calculations were performed using the Metropolis Monte Carlo (MMC) method. All pendant groups were treated as invariant except for the phosphorus groups which were allowed to rotate about the Cx-Ox and Ox-P bonds. The starting angles for the oligosaccharide were taken from the minimum energy conformers calculated for each disaccharide unit present in the molecule. 24-dimensional MMC calculations of the hexasaccharides with or without PEtn groups attached were carried out with 5000 macro moves. The graphics were generated using the Schakal software (Egbert Keller, Kristallographisches Institut der Universität, Freiburg, Germany).

### **Antibodies**

#### **Rabbit polyclonal antibody**

We used a rabbit polyclonal antibody specific for Group B *Neisseria meningitidis* capsular polysaccharide obtained by immunising a rabbit six times sub-cutaneously with lysates of MC58 at 2-week intervals. The first and second immunisations contained Freund's complete adjuvant and Freund's incomplete adjuvant respectively. Serum was obtained from bleed 6.

To increase specificity for the Group B capsular polysaccharide, rabbit polyclonal antibody (1 ml) was incubated overnight at 4°C with ethanol-fixed capsule-deficient MC58 ( $5 \times 10^9$  org./ml). This pre-adsorbed polyclonal antibody did not react with a capsule-deficient mutant of MC58 using immunofluorescence microscopy.

### **Monoclonal antibodies to inner core LPS**

Murine monoclonal antibodies to H44/76 *galE* LPS were prepared by standard methods. Briefly, 6-8 week old Balb/c mice were immunised three times intraperitoneally followed by one intravenous injection with formalin-killed *galE* mutant whole cells. Hybridomas were prepared by fusion of spleen cells with SP2/O-Ag 14 (Shulman, M., C.D. Wilde, and G. Kohler. 1978. Nature 276: 269-270) as described (Carlin, N.I., M.A. Gidney, A.A. Lindberg, and D.R. Bundle. 1986. J Immunol 137: 2361-2366). Putative hybridomas secreting *galE* specific antibodies were selected by ELISA employing purified LPS from L3 and its *galE* mutant and L2. Ig class, subclass and light chain were determined by using an isotyping kit (Amersham Canada Ltd, Oakville, Ontario). Clones were expanded in Balb/c mice following treatment with pristane to generate ascitic fluid. Spent culture supernatant was collected following in vitro culture of hybridoma cell lines. Further testing of *galE* MAbs was carried out by screening against purified LPS from *Neisseria meningitidis* L3 *lgtA*, *lgtB* and *lgtE* mutant strains (Figure 1), and *Salmonella typhimurium* Ra and Re mutants. One of the MAbs, MAb B5 (IgG<sub>3</sub>), was selected for more detailed study.

### **Immunotyping monoclonal antibodies**

To determine the immunotypes of *Neisseria meningitidis* Strains studies, especially L2 and L4-L6, the following murine MAbs were used in dot blots and whole cell ELISA: MN42F12.32 (L2,5), MN4A8B2 (L3,7,9), MN4C1B (L4,6,9), MN40G11.7 (L6), MN3A8C (L5) (Scholten, R.J., *et al.*, J Med Microbiol 41: 236-243).

### **Human umbilical vein endothelial cell (HUVEC) assay**

Cultured human umbilical vein endothelial cells (HUVECs) were prepared as described previously (Virji, M., *et al.*, 1991. Microb Pathog 10: 231-245) and were infected with strains of *Neisseria meningitidis* for 3h at 37°C. *Neisseria meningitidis* strains were grown with in

*vitro* or *in vivo* using the chick embryo model (as described above). The accessibility of the inner core LPS epitopes of whole-cell *Neisseria meningitidis* to specific MAb B5 was determined using immunofluorescence and confocal microscopy. Gelatin-coated glass coverslips coated with HUVECs were infected with wild-type *Neisseria meningitidis* as described previously (Virji, M., *et al.*, 1991. Mol Microbiol 5: 1831-1841), except bacteria were fixed with 0.5% paraformaldehyde for 20 min instead of methanol. For accessibility studies, coverslips were washed with PBS, blocked in 3% BSA-PBS and incubated with MAb B5 culture supernatant and pre-adsorbed polyclonal rabbit anti-capsular antibody. Binding of antibody to wild-type *Neisseria meningitidis* strains was detected by anti-mouse IgG rhodamine (TRITC) (Dako) and anti-rabbit IgG fluorescein (FITC) (Sigma). HUVECs were stained using diaminophenylamine DAPI (1µg/ml) (Sigma). Mounted coverslips were viewed for immunofluorescence using appropriate filters (Zeiss Microscope with Fluorograbber, Adobe Photoshop or confocal microscope (Nikon Model)).

## ELISA

### Purified LPS ELISA

A solid phase indirect ELISA employing purified LPS was used to determine the binding specificities of MAbs. Nunc maxisorp plates were coated overnight with 1.0µg/well of purified LPS derived from wild type and mutants. LPS (10µg/ml) was diluted in 0.05M carbonate buffer containing 0.02M MgCl<sub>2</sub>, pH 9.8. Non-specific binding sites were blocked for 1h with 1% BSA-PBS (Sigma) and washed three times with PBS Tween 20 (0.05% v/v) (PBS-T). Plates were incubated for 1h with MAb B5 culture supernatant and washed three times in PBS-T. Primary antibody was detected using anti-mouse IgG-alkaline phosphatase (Sigma: Cedarlane Laboratories Ltd.) incubated for 1h, washed three times in PBS-T, and detected using p-nitrophenyl phosphate AP substrate system (Sigma: Kirkegaard & Perry Laboratories). The reaction was stopped after 1h with 50µl 3M NaOH and absorbance determined at OD A<sub>405-410nm</sub> (Dynatech EIA plate reader).

### Inhibition ELISA

For inhibition ELISA studies, MAb B5 was incubated with purified LPS samples prior to addition to L3 *galE* LPS coated plates and assayed as described above.

### Whole cell ELISA

Whole cell (WC) ELISA was performed using heat-inactivated lysates of *Neisseria meningitidis* organisms as described previously (Abdillahi, H., and J.T. Poolman. 1988. J Med Microbiol 26:177-180). Nunc Maxisorp 96-well plates were coated with 100µl bacterial suspension (OD of 0.1 at A<sub>820nm</sub>) overnight at 37°C, blocked with 1% BSA-PBS and identical protocol followed as for LPS ELISA.

### Dot blots

Bacterial suspensions prepared as above (2µl) were applied to a nitrocellulose filter (45 micron, Schleicher and Schueller) and allowed to air dry. The same procedure as described for WC ELISA was followed except the detection substrate was 5-bromo-4-chloro-3-indoyl-phosphate/nitroblue-tetrazolium (BCIP/NBT) (2mg/ml; Sigma). The colour reaction was stopped after 30 min by several washes with PBS and blots were air-dried.

### Results

To investigate the potential of inner core LPS structures of *Neisseria meningitidis* as vaccines, we have studied the reactivity of an isotype IgG<sub>3</sub> murine monoclonal antibody (MAb), designated B5, raised against *Neisseria meningitidis* strain H44/76 immunotype L3 *galE* mutant. MAb B5 was one of seven monoclonal antibodies to LPS inner core produced against *Neisseria meningitidis* immunotype L3 *galE* by standard immunological methods (see Methods). Preliminary ELISA testing showed B5 cross-reacted with LPS from L3 parent strain and with *galE* (*lgtE*), *lgtA* and *lgtB* mutants, but did not cross-react with *Salmonella typhimurium* Ra or Re LPS.

In order to determine the specific inner core epitope recognised by MAb B5, various *Neisseria meningitidis* strains of known structure were examined in ELISA for cross reactivity (Figure 2). The most significant finding of this analysis was that *Neisseria meningitidis* immunotype L4 LPS was not recognised by MAb B5. The only structural difference between

In order to prove the essential inclusion of PEtn in the epitope recognised by MAb B5, immunotype L8 O-deacylated (odA) LPS was dephosphorylated (48% HF, 4°C 48h) (Figure 3). The absence of PEtn following dephosphorylation was confirmed by ES-MS analysis. As indicated in Figure 4, dephosphorylation of L8 odA LPS abolished reactivity to MAb B5. To further characterise the epitope recognised by MAb B5, several structurally defined genetic mutants of immunotype L3 were screened for cross-reactivity (Figure 4). The highly truncated LPS of mutant strain *icsB* was only weakly recognised, while mutant strain *icsA* LPS was not recognised by MAb B5. These results suggest that the presence of glucose on the proximal heptose residue (HepI) is not absolutely necessary for binding by B5 but is required for optimal recognition (Figure 1). Furthermore, MAb B5 does not bind LPS in which both the glucose on the  $\alpha$ -chain, HepI, and the N-acetylglucosamine residue on the  $\beta$ -chain, HepII, are absent. This suggests that the presence of N-acetylglucosamine is required to present the PEtn residue in the correct conformation for binding by MAb B5. Genetic modifications that produce severely truncated LPS glycoforms were also examined for reactivity with MAb B5. LPS from immunotype L3 *lsi* which has a trisaccharide of Hep-Kdo-Kdo attached to lipid A, and L3 PB4 which only contains the Kdo disaccharide and lipid A were not recognised by MAb B5 (Figure 4). Inhibition ELISA studies (data not shown) were in accord with this result, thus confirming the specificity of MAb B5 to the PEtn molecule linked at the 3-position of HepII.

To demonstrate the ability of MAb B5 to recognise this inner core epitope in encapsulated strains, we devised an assay in which natural isolates of *Neisseria meningitidis* were studied when they were grown on and became adherent to tissue cultured cells (HUVECs). Initially, this methodology was developed using the fully encapsulated strain MC58. The advantages of using the HUVEC assay were that they provided a monolayer of endothelial cells to which the bacteria could adhere and that they provided a biologically relevant environment. Previous attempts using *Neisseria meningitidis* directly adherent to gelatin- or matrigel-coated coverslips resulted in low numbers of adherent bacteria after repeated washings and high non-specific background staining.

Primary antibodies, MAb B5 and a polyclonal anti-capsular antibody were detected by anti-mouse TRITC and anti-rabbit FITC respectively. This demonstrated that an inner core LPS epitope of the fully encapsulated strain (MC58) was accessible to MAb B5 (Figure 5a). Confocal microscopy showed that MAb B5 and anti-capsular antibodies co-localised. In addition to this *in vitro* demonstration of accessibility of MAb B5 to inner core LPS, we also investigated organisms grown *in vivo* using the chick embryo model. Strain MC58 ( $10^4$  org./ml) was inoculated into chorio-allantoic fluid of 10 day old chick embryos and harvested the next day to provide *ex-vivo* organisms. The results of confocal microscopy were identical to those observed *in vitro*, that is MAb B5 and anti-capsular antibodies co-localised (Figure 5b). This demonstrated that the inner core LPS epitopes were also accessible *in vivo* on whole-encapsulated wild-type *Neisseria meningitidis*.

The observation of double staining of the inner core LPS epitope in the presence of capsule is key to the concept of this approach and therefore a number of controls were used to confirm the validity finding. These included: (i) double staining a MAb B5 negative e.g. immunotype L4 strain with MAb B5 and anti-capsular antibody. This resulted in no reactivity of MAb B5 on rhodamine filter but positive reactivity with anti-capsular antibody. This rules out a band-passing effect during the recording of the pictures; (ii) single staining of encapsulated MAb B5 positive strains with either MAb B5 alone or anti-capsular antibody alone followed by staining with rhodamine or FITC, respectively. When viewed on the appropriate wavelength there was no cross-reactivity during immunofluorescent staining nor any band-passing effect;

We obtained capsule-deficient and *galE* mutants from six of eight of the MAb B5 negative Group B strains (transformations were unsuccessful in the other two strains). Theses were



also negative with MAb B5 using dot blot, whole cell ELISA or immunofluorescence, with the exception of a BZ157 *galE cap-* mutant; which had low level reactivity both by immunofluorescence and dot blot. The MAb B5 strains were characterised using a battery of immunotyping MAbs. We determined the immunotype of the eight MAb B5 negative strains using combinations of the appropriate MAbs (see Methods) and dot blots of WC lysates (obtained from Peter van der Ley) (Table 3). In addition, structural fingerprinting of the inner core region of MAb B5 negative strains was performed by ES-MS on O-deacylated LPS from five of the respective capsule-deficient *galE* mutants (1000, NGE30, EG327, BZ157, NGH38) (Table 4). Strains 1000, NGE30, EG327 were non-typical by MAbs and LPS from these strains lacked PEtn on HepII of the inner core. BZ157, which corresponded to immunotype L2 by MAbs contained PEtn in the inner core, and by analogy to L2 at the 6/7 position of HepII (Table 3). NGH38 was immunotype L2, L5 and analogous to L2 by structural analysis. Those strains that were non-typable failed to react with MAbs that recognise L3,7,9, L6, L2,5, L4,6,9. However, 15/17 MAb B5 negative *Neisseria meningitidis* strains (all serogroups) were positive for L2, 5 and all MAb B5 positive strains were positive for L3,7,9,. No reaction with any immunotyping MAbs was observed with 8/32 MAb B5 negative strains and 24/68 of MAb B5 positive strains.

To determine if the degree of sialylation of the LPS was a factor in the ability of MAb B5 to recognise its inner-core epitope, MAb B5 negative strains were examined by LPS gels. MAb B5 reactivity was unaffected by varying the state of sialylation through exposure to neuraminidase as described in methods (Figure 6). Furthermore, strain MC58, with which the MAb B5 reacted strongly, was found to be highly sialylated (Figure 6) and this was confirmed by ES-MS of purified O-deacylated LPS (data not shown). Therefore our data did not support a contribution of sialylation to the lack of MAb B5 reactivity.

With respect to the other *Neisseria* species, MAb B5 also recognised the inner core LPS of five strains of *Neisseria gonorrhoeae* (F62, MS11, FA19, 179008, 150002) (two were negative) and (at least) two strains of *Neisseria lactamica* (L19, L22). However, MAb B5 did not react with one strain each of *Neisseria polysaccharea* (M7), *Neisseria mucosa* (F1), *Neisseria cinerea* (Griffiss, J.M., J.P. O'Brien, R. Yamensaki, G.D. Williams, P.A. Rice, and

H. Schneider. 1987. Infect Immun 55: 1792-1800), *Neisseria elongata* (Q29), *Neisseria sicca* (Q39) and *Neisseria subflava* (U37). Also MAb B5 did not react with *Escherichia coli* (DH5 alpha), *Salmonella typhimurium* (LT2) or its isogenic LPS mutants (*rfaC*, *rfaI*, *rfaP*).

Finally, we investigated the reactivity of MAb B5 with 100 strains that included representatives of serogroups A, B, C, W, X, Y and Z (Maiden, M.C.J., *et al.*, 1998. PNAS 95: 3140-3145). Of these strains, 70% were MAb B5 positive. Clustering according to genetic relatedness was evident. For example, none of the MAb B5 negative stains were in the ET5 complex. Among Group A strains, MAb B5 positive and negative stains also fell into distinct clusters. For example, lineages I-III and lineage A4 were positive and lineage IV-I was negative. This collection, together with that described in (Seiler, A., *et al.*, 1996. Mol Microbiol 19: 841-856) represents the most complete set available for known hyperinvasive lineages in all major serogroups of *Neisseria meningitidis* strains.

## Discussion and Conclusions

The pre-requisites for any candidate *Neisseria meningitidis* Group B vaccine would be that it contains a highly conserved epitope(s) that is found in all Group B stains and is accessible to antibodies in the presence of capsule. Our approach has combined genetics, structural analysis and immunobiology to define candidate epitopes in inner core LPS of *Neisseria meningitidis* Group B. This study uses murine MAb B5, isotype IgG3, which was raised to a genetically defined immunotype L3 *galE* mutant in order to specifically target inner-core LPS epitopes. The epitope(s) recognised by MAb B5 was defined by cross-reactivity studies with purified LPS glycoforms of known structure. MAb B5 recognised all LPS glycoforms in which the PEtn is at the 3-position of HepII (immunotypes L1, L3, L7, L8 and L9) and failed to react with immunotypes where PEtn is at the 6- or 7- position (L2, L4 and L6) or absent from HepII (L5) (Figure 1). MAb B5 reacted with 70% *Neisseria meningitidis* strains tested from the two most complete sets of *Neisseria meningitidis* strains available world-wide (Seiler, A., *et al.*, 1996. Mol Microbiol 19: 841-856, 35). Of these strains, 76% of *Neisseria meningitidis* Group B strains tested were positive with MAb B5 and 70% of a collection that included all *Neisseria meningitidis* serogroups tested was positive with MAb B5. Therefore,

it may be envisaged that a vaccine containing a limited number of glycoforms, representing all the possible PEtn positions (none, 3 and 6/7) on HepII on the inner core, would cover 100% of *Neisseria meningitidis* Group B strains.

The LPS structures of MAb B5 negative strains were confirmed by structural analysis. Two structural variants were recognised. One variant without PEtn in the inner core LPS (e.g. NGE30, EG327, 1000); and the other, with PEtn group of HepII (e.g. BZ157, NGH38) at the 6- or 7- position instead of the 3-position.

With a view to developing inner core LPS epitopes as vaccine candidates, it is significant that there were no effects of the capsule on MAb B5 accessibility, as shown by co-localisation of the anti-capsule antibody and MAb B5 in wild-type organisms (MC58) grown *in vitro* and *in vivo* by confocal microscopy (Figures 5a and b). Nor did the presence or absence of sialic acid have an effect since both MAb B5 positive and negative strains had high sialylation states as shown by tricine gels (Figure 6) and confirmed by ES-MS (data not shown).

There was no evidence of phase variation in MAb B5 positive or negative strains in this study, with the exception of one strain (BZ157) which had a very low level of MAb B5 positive strains in parent and *galE* mutant (0.06%) (data not shown). Structural analysis of LPS extracted from these two variants is currently under investigation.

Three dimensional space filling models of the inner core LPS of L3 and L4 immunotypes show that the position of the PEtn, either 3- or 6-position respectively (shown in brown), alters the accessibility and conformation of PEtn in the inner core epitope (Figure 3). The most striking example of the importance of PEtn for MAb B5 reactivity was observed when PEtn was removed from the immunotype L8 (MAb B5 positive) by treatment with hydrogen fluoride (HF) which totally abolished MAb B5 reactivity.

Previous studies with oligosaccharide conjugates in mice and rabbits have demonstrated that PEtn is important in immunogenicity and functional activity of polyclonal antibodies (Verheul, A.F., *et al.*, 1991. *Infect Immun* 59: 843-851). These studies identified two sets of

polyclonal antibodies. One set resulting from L1 and L3,7,9 oligosaccharides had PEtn in the 3-position of HepII, were immunogenic, had opsonophagocytic (OP) and chemiluminescence in oxidative burst reaction, but had no serum bactericidal activity. The other set of antibodies resulting from L2 conjugates (6- or 7-position or without PEtn at HepII) were poorly immunogenic and had greatly reduced OP activity and chemiluminescence (Verheul, A.F., A.K. Braat, J.M. Leenhouts, P. Hoogerhout, J.T. Poolman, H. Snippe, and J. Verhoef. 1991. Infect Immun 59: 843-851). Future studies will look at the safety and immunogenicity of inner core LPS-conjugates (PEtn at 3-position of HepII and alternative glycoforms) and the functional ability of these polyclonal antibodies in opsonic and serum bacterial assays, initially in mice and rabbits. Preliminary studies using MAb B5 in an opsonophagocytosis assays with *Neisseria meningitidis* strain MC58 and donor human polymorphonuclear cells suggest MAb B5 is opsonic in the presence of complement and that the uptake of *Neisseria meningitidis* bacteria correlates with an oxidative burst reaction within the neutrophil. MAb B5 does not appear to have any significant serum bactericidal activity with *Neisseria meningitidis* strain MC58, however this is not unexpected in view of its isotype (IgG3). The functionality of MAb B5 is currently under further investigation.

In conclusion, MAb B5 recognises a conserved inner core epitope in which the PEtn is at the 3-position of HepII. This epitope was present in 76% *Neisseria meningitidis* Group B strains and 70% of all *Neisseria meningitidis* serogroups, and was accessible in the presence of capsule. A limited number of alternative glycoforms have been identified that are not recognised by MAb B5 where the PEtn is either absent or at an exocyclic position of HepII. Therefore, a vaccine containing a limited number of glycoforms might give 100% coverage of all *Neisseria meningitidis* Group B strains.

**Table 1. Bacterial strains.**

Species Strain	Relevant	Source/reference
	immunotype (bold) and genotype (italics)	

Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
<i>Neisseria meningitidis</i>		
MC58	<b>L3</b>	CSF isolate Virji, M., H. Kayhyt, D.J.P. Ferguson, J.E. Heckels, and E.R. Moxon. 1991. Mol Microbiol 5:1831-1841.
H44/76	<b>L3</b>	Holton, E. 1979. J Clin Microbiol 9:186-188.
MC58	<i>galE</i>	Jennings, M.P., P. van der Ley, K.E. Wilks, D.J. Maskell, J.T. Poolman, and E.R. Moxon. 1993. Mol Microbiol 10:361-369.
MC58	<i>lsi1(rfaF)</i>	Jennings, M.P., M. Bisercic, K.L. Dunn, M. Virji, A. Martin, K.E. Wilks, J.C. Richards, and E.R. Moxon. 1995. Microb Pathog 19:391-407.
MC58	<i>lgtA</i>	Jennings, M.P., D.W. Hood, I.R. Peak, M. Virji, and E.R. Moxon. 1995. Mol Microbiol 18:729-740.
MC58	<i>lgtB</i>	Jennings, M.P., D.W. Hood, I.R. Peak, M. Virji, and E.R. Moxon.

Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
		1995. Mol Microbiol 18:729-740.
H44/76	<i>rfaC</i>	Stolljokovic, I., V. Hwa, J. Larson. L. Lin, M. So, and X. Nassif. 1997. FEMS Microbial Lett 151:41-49.
H44/76	<i>icsA</i>	van der Ley, P., M. Kramer, A. Martin, J.C. Richards, and J.T. Poolman. 1997. FEMS Microbiol Lett 146:247-253.
H44/76	<i>icsB</i>	van der Ley, P., M. Kramer, A. Martin, J.C. Richards, and J.T. Poolman. 1997. FEMS Microbiol Lett 146:247-253.
126E; 35E;H44/76;89I;M981; M992 6155;892257;M978;120 M;7880; 7889;3200	<b>L1-L12 RESPECTIVELY</b>	Poolman, J.T., C.T.P. Hopman, and H.C. Zanen. 1982. FEMS Microbial Lett 13:339-348.
BZ157	<b>L2</b>	Seiler, A., R. Reinhart, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
BZ157 1000	<i>galE</i> <b>NT</b>	This study Seiler, A., R. Reinhart, J. Sakari,

Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
		D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
1000	<i>galE</i>	This study
NGE30	<b>NT</b>	Seiler, A., R. Reinhart, J. Sakari. D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
NGE30	<i>galE</i>	This study
EG327	<b>NT</b>	Seiler, A., R. Reinhart, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
EG327	<i>galE</i>	This study
NGH38	<b>L2,5</b>	Seiler, A., R. Reinhart, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
NGH38	<i>galE</i>	This study
EG328	<b>NT</b>	Seiler, A., R. Reinhart, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.
EG328	<i>galE</i>	This study
3906;NGH15;BZ133;B Z83;EG329; SWZ107;BZ198;NGH4		Seiler, A., R. Reinhart, J. Sakari, D.A. Caugant, and M. Achtman. 1996. Mol Microbiol 19:841-856.

WO 01/22994

PCT/GB00/03758

39

Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
1;NG4/88; 2970;BZ147;NGG40;N GH36;NG3/88; NGF26;NG6/88;NG H38;NGE28;BZ169; 528;DK353;BZ232;DK 24;BZ159;BZ10; BZ163;NGP20 B40;Z4024;Z4081;Z24 91;Z3524;Z3906;Z5826 ;BZ10;BZ163;B6116/7 7;L93/4286; NG3/88;NG6/88;NGF2 6;NGE31;DK24; 3906;EG328;EG327;10 00;B534;A22;71/94;86 0060;NGG40;NGE28; NGH41;890326;860800 ;NG4/88;E32;44/76;204 /92;BZ8; SWZ107; NGH38;DK353; BZ232; E26; 400; BZ198; 91/40; NGH15; NGE30; 50/94; 88/03415; NGH36; BZ147;297-0		(35)
<i>Neisseria lactamica</i>		Brian Spratt & Noel Smith



Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
(L12,L13,L17,L18,L19, L20,L22) <i>polysaccharea</i> (P4), <i>mucosa</i> (M7), <i>cinerea</i> (F1), <i>elongata</i> (I8), <i>sicca</i> (Q29), <i>subflava</i> (U37)		
<i>Neisseria gonorrhoeae</i> : F62,MS11,FA19,FA10 90,179008, 150002,15253 SN-4 P9-2		R.Goldstein   Staffan Normavk M.Virji
<i>Haemophilus influenzae</i> type b Eagan; 7004; Rd 5B33; 3Fe;E3Fi;E1B1	<i>opsx</i> <i>rfaF</i> <i>orfH</i>	Hood, D.W., M.E. Deadman, T. Allen, H. Masoud, A. Martin, J.R. Brisson, R. Fleischman, J.C. Venter, J.C. Richards, and E.R. Moxon. 1996. Mol Microbiol 22:951-964.
PLAK33	<i>lpxA</i>	Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der Ley. 1998. Nature 392:449-450.
<i>Haemophilus somnus</i> ;		J.Richards

Species Strain	Relevant immunotype (bold) and genotype (italics)	Source/reference
738 L1		
Non-typable		J. Eskola
<i>Haemophilus influenzae</i>		
(NTHI): 54, 375, 477,		
1003, 1008, 1042,		
1147,1231		
<i>E. coli</i>		Neidardt, F.C. 1996. Roy Curtiss
DH5a		III, J.L. Ingraham, E.C. Lin, K.
		Brooks, B. Magasanik, W.S.
		Reznikoff, M. Riley, S.M. and H.E.
		Umbarger (ed.), ASM Press.
<i>Salmonella</i>		Schnaitman, C.A., and F.D. Klena.
<i>typhimurium</i>	<i>rfaC</i>	1993. 57:655-682.
LT2	<i>rfaI</i>	
	<i>rfaP</i>	

Table 2. Reactivity of monoclonal antibody B5 with representative *Neisseria meningitidis* strains of immunotypes LI-L12 determined by whole cell ELISA, dot blots of lysates, immunofluorescence and confocal microscopy.

Strain	Serogroup: Serotype: Serosubtype	Immuno- type	Whole cell ELISA <sup>a</sup> (OD <sub>A405nm</sub> )	Dot Blot <sup>b</sup>	Immuno- fluorescence <sup>c</sup>
126E	C:3:P1.5,2	L1	+ 1.8	+++	+

WO 01/22994

PCT/GB00/03758

42

35E	C:20:P1.1	L2	- <0.4	-	-
H44/76	B:15:P1.7,16	L3	+ 1.3	+++	++
89I	C:nt:P1.16	L4	- <0.4	-	-
M98I	B:4:P1.-	L5	- <0.4	+/-	-
M992	B:5:P1.7,1	L6	- <0.4	+/-	-
6155	B:nt:P1.7,1	L7	+ 0.8	++	+
M978	B:8:P1.7,1	L8	+ 1.9	+++	++
892257	B:4:P1.4	L8	+ 1.9		
120M	A:4:P1.10	L9	+ 1.8	+++	+
7880	A:4:P1.6	L10	+ 2.2	+++	+
7889	A:4:P1.9	L11	+ 2.0	+++	++
3200	A:4:P1.9	L12	+ 2.1	+++	++

<sup>a</sup> Positive reactivity (OD<sub>A405</sub> > 0.4) (+), negative reactivity (OD<sub>A405</sub> < 0.4) (-).

<sup>b</sup> Strongly positive (+++), positive (++), weakly positive (+/-), negative (-).

<sup>c</sup> Strongly positive (++), positive (+), negative (-).

**Table 3**

Correlation between reactivity with monoclonal antibody B5, immunotyping and location of phosphoethanolamine (PEtn) on HepII of inner core.

Strain	MAb B5	Immuno-type	Position of PEtn on HepII	
			O-3	O-6
MC58	+	L3,7	+	-
1000	-	NT	-	-
NGE30	-	NT	-	-
EG327	-	NT	-	-
BZ157 <sup>‡</sup>	-	L2,5	-	+
BZ157 <sup>§</sup>	+	L3,7	+	-
NGH38	-	L2,5	-	+

Strain	Observed Ions ( <i>m/z</i> )		Molecular Mass (Da)		
	(M-2H) <sup>2-</sup>	(M-H) <sup>-</sup>	Observed	Calculated	Lipid A <sup>b</sup>
1000	1213.0	2427.6	2427.7	2427.2	1075
	1252.9	2507.8	2507.8	2507.2	1155
	1314.5	2630.9	2630.9	2630.3	1278
NGH38	1293.8	2589.5	2589.3	2589.3	952
EG327	1151.2	2304.4	2304.4	2304.1	952
NGE30	1132.1	-	-	2265.1	1075

Strain	Observed Ions ( <i>m/z</i> )		Molecular Mass (Da)		
	(M-2H) <sup>2-</sup>	(M-H) <sup>-</sup>	Observed	Calculated	Lipid A <sup>b</sup>
	1396.1	2793.4	2793.7	2792.5	1075
	1436.0	2873.7	2873.9	2872.5	1155
	1498.0	2997.2	2997.1	2995.6	1278
BZ157	1274.6	2551.4	-	2550.3	1075
	1314.8	2631.1	2631.2	2630.3	1155
	1376.4	2754.4	2754.5	2753.4	1278
	1457.5	2916.6	2916.6	2915.6	1278

<sup>a</sup> Glc, glucose; GlcNAc, N-acetylglucosamine; PEtn, phosphoethanolamine; Hep, heptose; Kdo, 3-deoxy-D-manno-octulosonic acid.

<sup>b</sup> As determined by MS-MS analyses.

Table 4 continued

Strain	Proposed Composition <sup>a</sup>
1000	2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
	2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
	2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A

<b>Proposed Composition <sup>a</sup></b>	
<b>Strain</b>	
NGH38	3Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
EG327	2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
NGE30	Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
	3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
	3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
	3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
BZ157	2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
	2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
	2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
	3Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A

<sup>a</sup> Glc, glucose; GlcNAc, N-acetylglucosamine; PEtn, phosphoethanolamine; Hep, heptose; Kdo, 3-deoxy-D-manno-octulosonic acid.

<sup>b</sup> As determined by MS-MS analyses.

### Figure Legends - Example 1

## Figure 1

Representation of the structure of meningococcal LPS oligosaccharides of immunotypes L1-L9. Immunotypes are indicated to the extreme left. The vertical dotted line marks the junction between the inner core structures to the right and outer core structures to the left. The epitope recognised by MAb B5 is indicated in bold (MAb B5 positive). Arabic numerals indicate the linkage between sugars or amino-sugars. Alpha and beta indicate the carbon 1 linkage at the non-reducing end of the sugar. Genes for incorporating each of the key sugars or amino-sugars into the LPS oligosaccharide in the biosynthetic pathway are indicated with arrows indicating where in the pathway the gene product is required. Abbreviations include: Kdo, 2-keto-2-deoxyoctulosonic acid; PEtn, phosphoethanolamine; Gal, galactose; GLcNAc, N-acetyl glucosamine; Glc, glucose; Hep, Heptose. Immunotype L5 has no PEtn on the second heptose. The gene that adds the glucose to the second heptose (*lgtG*) is phase-variable.

## Figure 2

Cross-reactivity of MAb B5 with selected immunotypes and mutants of *Neisseria meningitidis* LPS and *O*-deacylated (odA) LPS as determined by solid phase ELISA. LPS glycoforms of immunotypes L2 (35E) (solid black bars), L3 (H44/76) (open bars), L4 (891) (diagonal line filled bars), L5 (M981), L8 (M978) (horizontal line filled bars), wild-type and respective mutants (*galE*, *lgtA* or *lgtB*), in a native or *O*-deacylated form, were coated onto ELISA plates (see methods) and reactivity of MAb B5 determined by standard ELISA (OD A<sub>410nm</sub>).

## Figure 3

Space-filling 3-D molecular models of the calculated (MMC) lowest energy states of the core oligosaccharide from *galE* mutants of (a) L3, (b) L4 and (c) L8-dephosphorylated. Kdo moiety indicated in grey is substituted at the O-5 position by the heptose disaccharide inner-core unit (red), HepI provides the point via a glucose residue (dark green) for extension to give  $\alpha$ -chain epitopes, while HepII is substituted by N-acetyl glucosamine residue (lighter green) at O-2. PEtn (brown) is shown in O-3 position in L3 immunotype and O-6 in L4 immunotype. Colour versions of this and the other figures for Example 1 are to be found in Plested *et al.*, 1999 Infect. Immunity 67, 5417 - 5426.

Figure 4

Cross-reactivity of MAb B5 with genetically modified L3 LPS and chemically modified L8 LPS from *Neisseria meningitidis* as determined by solid phase ELISA. LPS glycoforms of immunotype L8 (M978) (horizontal line filled bars) chemically modified by O-deacylation and HF treatment and immunotype L3 (H44/76) (open bars) *galE*, *icsB*, *icsA*, *lsi*, PB4 mutants (*O*-deacylated) were coated onto ELISA plates (see methods) and reactivity of MAb B5 determined by standard ELISA ( $OD_{A410nm}$ ).

Figure 5.a.

Confocal immunofluorescence microscopy of *Neisseria meningitidis* organisms, strain MC58 adherent to human umbilical vein endothelial cells (HUVECs). (a) Fluorescein tagging with rabbit polyclonal antibody specific for Group B *Neisseria meningitidis* capsule. (b) rhodamine tagging of MAb B5, specific for *galE* LPS (x2400 magnification). Confocal immunofluorescence microscopy of *in vivo* grown MC58 organisms stained as described in Plested *et al.*, 1999 Infect. Immunity 67, 5417-5426. (c) anti-capsular antibody (green). (d) MAb B5 (red) (x2400 magnification).

Figure 6

Silver-stained tricine gels of LPS preparations (10µg/lane) from *Neisseria meningitidis* Group B strains which were not reactive with MAb B5. These LPS preparations were either not treated (-) or treated with (+) neuraminidase to show the presence of sialic acid: a) MAb B5 negative strains Lanes 1,2 = NGE30; lanes 3,4 = BZ157; lanes 5,6 = EG328; lanes 7,8 = 1000; lanes 9,10 = 3906. b) MAb B5 negative strains: Lanes 1,2 = EG327; lanes 3,4 = NGH38; lanes 5,6 = NGH15; MAb B5 positive strain: lanes 7,8 = MC58. Presence of sialic acid (NeuAc) indicated by →. This band was seen in untreated (-) and removed in treated (+) neuraminidase preparations.

## Example 2 Identification of additional inner core epitopes



## INTRODUCTION

Example 1 identifies an inner core LPS epitope that was accessible and conserved in 70% of a global collection of 104 *Neisseria meningitidis* strains representative of all major serogroups (Plested *et al.*, 1999, Infect. Immunity 67, 5417 - 5426). The epitope recognised by MAb B5 was identified in all LPS immunotypes with phosphoethanolamine (PEtn) in the 3-position of  $\beta$ -chain heptose (HepII) of inner core LPS. Further work was carried out to identify additional epitopes, with the aims outlined in Fig 4

### In summary:

A series of twelve murine monoclonal antibodies (MAbs) were developed at NRC, by using a procedure described previously by us (Plested *et al.*, 1999 Infect. immunity 67, 5417 - 5426), except using formalin-fixed *Neisseria meningitidis* L4 (strain 891) *galE* whole-cells. The twelve MAbs were extensively screened by ELISA using purified LPS from *Neisseria meningitidis* mutants and wild-type strains and three MAbs B2 (IgG2b), A4 (IgG2a), and A2 IgG2a were chosen for further investigation. Conservation of the inner core LPS epitope was assessed at Oxford using wild-type whole-cell lysates of a global collection of 104 *Neisseria meningitidis* disease isolates (Maiden, M.C.J., J.A. Bygraves, E. Feil, G. Morelli, J.E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D.A. Caugant, I.M. Feavers, M. Achtman, and G.B. Spratt. 1998. PNAS 95: 3140-3145). Accessibility of the inner core LPS epitope was assessed using immunofluorescence microscopy with ethanol-fixed *Neisseria meningitidis* whole-cells of wild type and mutants adherent to a monolayer epithelial cells (Plested *et al.* 1999).

Each of the three MAbs reacted with purified *Neisseria meningitidis* L4 *galE* LPS by ELISA. Except for MAb B2 that had low reactivity with *Neisseria meningitidis* L4 LPS, none of the *Neisseria meningitidis* L4 series of MAbs were able to recognise wild-type L4 or L2 purified LPS by ELISA. None of the *Neisseria meningitidis* L4 MAbs recognised *Neisseria meningitidis* wild-type L2 or L4 whole-cells by immunofluorescence microscopy.

MAb B2 reacted with 15/32 *Neisseria meningitidis* MAb B5 negative *Neisseria meningitidis*

strains and 9/68 *Neisseria meningitidis* MAb B5 positive *Neisseria meningitidis* strains by whole-cell dot blot analysis. MAb 2 reacted with L4 *galE*, L4 wild-type (very low reactivity) but not L3 *galE*, L2 *galE* (native/O-deacylated (odA)), L2 wild-type (native-odA), L5, L6 wild-type LPS.

MAb A2 recognised 28/32 *Neisseria meningitidis* MAb B5 negative *Neisseria meningitidis* strains and 20/68 *Neisseria meningitidis* MAb B5 positive *Neisseria meningitidis* strains by whole-cell dot blot analysis. MAb A2 reacted with L4 *galE* (native/odA), L2 *galE* (native) but not L3 *galE*, L2 *galE* (odA), L2 wild-type (native/odA), L4, L5, L6 wild type LPS.

MAb A4 reacted with 29/32 *Neisseria meningitidis* MAb B5 negative *Neisseria meningitidis* strains and 24/68 *Neisseria meningitidis* MAb B5 positive *Neisseria meningitidis* strains by whole-cell lysate dot blot analysis. MAb A4 reacted with L4 *galE*, L2 *galE* (native/odA), but not L3 *galE*, L2 wild type, L4, L5, L6, L8 wild-type LPS.

Based on these results, MAb A4 (IgG2a) was chosen for further study as it demonstrated specificity for both L4 *galE* and L2 *galE* LPS by ELISA and recognised all except 3 *Neisseria meningitidis* B5 negative *Neisseria meningitidis* strains (BZ232 serogroup B; NGH38 serogroup B; F1576 serogroup C). Together MAbs B5 and A4 were able to recognise 97/100 *Neisseria meningitidis* isolates. Immunofluorescence microscopy demonstrated that MAb A4 was able to access the inner core epitope in an L4 *galE* mutant in the presence of capsule.

We have identified LPS inner-core epitopes with PEtn at the 3-position of HepII (MAb B5) or not at the 3 position (MAb A4). There remain 3 strains out of 100 (BZ232, NGH38 and F1576) which show no reactivity with either MAb A4 or MAb B5. The structural basis for this non-reactivity is under investigation. Once all the variant glycoforms of the inner core are known, of which at least 3 have been identified, the rationale will exist for including epitopes, representative of all *Neisseria meningitidis* strains causing invasive disease, in a conjugate vaccine. This will be tested for proof in principle using studies in animals before proceeding to human trials.

The following techniques were used :

(1) Murine MAb A4 (IgG2a) was raised to *galE* (89I, L4 immunotype) and selected on basis of reactivity in LPS ELISA & immunofluorescence (IF) microscopy.

(2) LPS ELISA (Plested *et al.*, 2000 J. Immunol. Meth. 237:73-84): Microtitre plates (Nunc) coated with purified (*galE*) LPS (10µg/ml) overnight, were washed, blocked, incubated with MAb for 1h, washed and detected with anti-mouse IgG alkaline phosphatase and p-NPP (OD<sub>A405nm</sub>).

(3) Immunoblotting using whole-cell lysates from 104 *Neisseria meningitidis* strains (Plested *et al.*, 1999 IAI 67:5417-5426). MAb A4 was detected using anti-mouse IgG alkaline phosphatase and BCIP/NBT.

(4) Immunofluorescence microscopy: as before (Plested *et al.*, 1999 IAI 67:5417-5426) or *Neisseria meningitidis* were adherent to cultured human buccal epithelial cell line (16HBE140) instead of HUVECs; fixed, blocked, incubated with MAb A4 and anti-capsular serogroup B antibody then detected using fluorescently labelled secondary antibodies (TRITC or FITC).

(5) Fine structural analysis of purified *O*-deacylated LPS samples by negative-ion ES-MS and NMR (Plested *et al.*, 1999 IAI 67:5417-5426).

## RESULTS:

### 1) Accessibility of LPS epitope in *Neisseria meningitidis* whole-cells.

See Figure 7.

MAB A4 accesses the inner core LPS epitope in *Neisseria meningitidis* L4 *galE* mutant in the presence of capsule (magnification x 100). *Neisseria meningitidis* L4 *galE* adherent to epithelial cells (16HBE140) stained with:

- a. MAb A4 (anti-mouse TRITC-red);
- b. anti-cap B (anti-rabbit FITC- green);
- c. triple staining with MAb A4 (anti-mouse TRITC-red), anti-cap B (anti-rabbit FITC-green) and epithelial cells stained DAPI (blue).

MAB B5 accesses inner core LPS epitopes in *Neisseria meningitidis* L3 MC58 (magnification x 2400). *Neisseria meningitidis* L3 MC58 adherent to HUVECs stained with d. MAb B5 (anti-mouse TRITC-red), e. anti-cap B (anti-rabbit FITC-green) using confocal immunofluorescence microscopy.

## 2) Conservation of LPS epitope across all serogroup of *Neisseria meningitidis*

See Figure 8.

MAB A4 (diagonal hatched) and MAB B5 (horizontal lines) together recognise all *Neisseria meningitidis* strains by immunoblotting with whole-cell lysates, except 3 strains (black-arrows) which are under further analysis. The dendrogram of genetic relationship of *Neisseria meningitidis* strains from a global collection was constructed by cluster analysis following Multi-Locus Sequence Typing (MLST) (Maiden *et al.*, 1998 PNAS 95:3140-3145).

## 3) Genetically defined LPS structure

See Figure 3.

Fine LPS structural details demonstrates conformational effects of PEtn on epitope presented. Space-filling 3-D molecular models of (Metropolis Monte Carlo) calculated lowest energy states of core LPS from *galE* mutants a. L3; b. L4; c. L8 (dephosphorylated). Kdo in grey,

Heptose (Hep) in red, Glucose (Glc) and Glucosamine (GlcNAc) in light and darker green, (PEtn) in brown.

## CONCLUSIONS:

Inner core glycoforms have been identified with PEtn in the 3-position of HepII, an exocyclic position of Hep II or absent. This study has indicated that utilisation of MAb A4 in conjunction with MAb B5 enables 97% of meningococcal strains to be recognised. These studies therefore indicate that inner core LPS may have potential as a *Neisseria meningitidis* serogroup B vaccine.

**Example 3 Studies on the functional activity of monoclonal antibody, MAb B5, and inner core (*galE*) lipopolysaccharide antibodies in human serum using an opsonophagocytosis assay, a serum bactericidal assay and an *in vivo* passive protection model**

## INTRODUCTION

We have generated a monoclonal antibody, MAb B5. This antibody is accessible to inner core LPS structures in *Neisseria meningitidis* in the presence of capsule and is conserved in 70% of a representative collection of *Neisseria meningitidis* of all strains and 76% of serogroup B strains (Plested, J.S. *et al.* (1999) Infect. & Immun. 67 (10): 5417-5426).

Until now it was not known if antibodies in a natural human infection can be specific for MAb B5 epitope and have functional activity.

MAb B5 has been shown to have opsonic and bactericidal activity against *galE* mutant and ability to passively protect infant rats against challenge with *Neisseria meningitidis galE* mutant using an *in vivo* model.

## METHODS

(1) **Opsonophagocytosis (OP) assay** (Plested *et al.*, 2000b): Briefly, fluorescently labelled ethanol-fixed *Neisseria meningitidis* MC58 or *galE* mutant or beads coated with purified *galE* LPS (10µg/ml) were opsonised with MAb B5 and human complement source diluted in final buffer for 10mins/37°C/ 500rpm in microtitre plate. Then human peripheral blood polymorphonuclear cells (PMNs) prepared from heparinised donor blood were diluted in final buffer and added to each well ( $1 \times 10^7$  cells/ml) and incubated for a further 10min/37°C/ 500rpm. Reaction mixture was stopped on ice by addition of 150µl PBS-EDTA and added to FACS tube containing 50µl Trypan Blue. Mixture was mixed and 10,000 lymphocytes were analysed on FACScan and Cellquest software. PMNs were analysed by FSC vs appropriate channels to determine % uptake of fluorescent bacteria by granulocytes and monocytes (% OP activity).

(2) **Serum Bactericidal (SB) assay** method was adapted from CDC protocol except MAb B5 was added to dilutions of human pooled sera and 1000 cfu of *Neisseria meningitidis* strain and incubation time was 40-45min at 37°C. Briefly, bacteria were grown up onto BHI agar overnight from frozen stocks. A suspension of bacteria in PBS-B was measured at OD<sub>260</sub> (1:50 in 1% SDS, 0.1% NaOH). Using a 96-well microtitre plate 50µl buffer was added to wells in columns 2-7. 50µl of 80% decomplexed human pooled sera was added to column 8 wells. 100µl of 80% pooled sera was added to wells in column 1. Two-fold serial dilutions of antibody were added to columns 1-7 (discarding the last 50µl from column 7). 50ul of bacterial suspension diluted to give 1000 cfu in 50µl were added to wells of columns 1-8. The mixture was incubated for 40-45 minutes and plated out onto BHI agar for overnight incubation. The number of colonies on each plate were counted and the results expressed as a % of cfu/ml in decomplexed control well.

(3) **In vivo passive protection model** using 5-day old Wistar infant rats model. This model was as described by Moe, G.R., *et al.*, 1999. Infect. Immun. 67: 5664-5675, except higher doses of *Neisseria meningitidis* bacteria were used and different *Neisseria meningitidis* strain

was used. Briefly, groups of 5 day old infant rats were randomised with mothers, weighed and given inoculum  $1 \times 10^8$  cfu/ml *Neisseria meningitidis galE* mutant mixed 1:1 with either (i) No antibody (PBS) (ii) Affinity purified MAb B5 (10 $\mu$ g) (iii) Affinity purified MAb B5 (100 $\mu$ g) (iv) MAb 735 (anticapsular group B antibody) (2 $\mu$ g). Infant rats were monitored for signs of infection and sampled by tail vein bleed at 6 hours post-infection. Animals were weighed and terminal bleed was taken after 24h by cardiac puncture following injection of pentobarbitone. Neat and diluted blood were plated immediately onto BHI plates and incubated overnight. Plates were counted next day to determine bacteremia (cfu/ml) at 6h and 24h.

(4) **LPS ELISA** (Plested *et al.*, 2000a. Microtitre plates (Nunc) coated with purified (*galE*) LPS (10 $\mu$ g/ml) overnight, were washed, blocked and incubated with MAb or human sera for 1h, washed and detected with anti-mouse or anti-human IgG alkaline phosphatase and p-NPP (OD<sub>A405nm</sub>).

(5) **Affinity purified MAb B5.** Spent culture supernatant from MAb B5 was purified on Protein A-sepharose column and eluted with Glycine pH 4.0, neutralised with Tris-HCl pH 9.0. Fractions were tested for reactivity on LPS ELISA, pooled and concentrated using Amicon-filter. Purity was determined by SDS-PAGE gel and protein concentration was determined by OD and protein assay.

**(6) FACS surface labelling of *Neisseria meningitidis* bacteria**

The method was adapted from Moe *et al.*, (Moe, G.R., *et al.*, 1999. Infect. Immun. 67: 5664-5675) except no sodium azide was included in the blocking buffer step (Plested *et al.*, 2000b. To prepare labelled bacteria *Neisseria meningitidis* (strain MC58, *galE*) organisms were grown overnight by standard conditions at 37°C on BHI agar plates and gently suspended in PBS. OD<sub>A260nm</sub> was adjusted to give the required concentration e.g.  $5 \times 10^9$  org./ml. 100 $\mu$ l bacterial cells were added to each FACS tube ( $5 \times 10^8$  org.) and an equal volume of diluted sera (1/100 MAb B5 in 1% BSA/PBS) was added. Tubes were incubated for 2 hours at 4°C and cells centrifuged for 5 minutes at 13,000 g. The supernatant was discarded and cells were washed with 200 $\mu$ l of 1% BSA/PBS. 100 $\mu$ l of FITC-conjugated F(ab)<sub>2</sub> goat anti-mouse

(Sigma F2772) was added, diluted 1:100 in 1% BSA/PBS, and tubes were incubated for 1 hour at 4°C. Cells were centrifuged at 13,000 g for 5 minutes and washed by addition of 200µl of 1% BSA/PBS. The supernatant was discarded and the cells were suspended in 1% v/v formaldehyde. Samples were transferred to FACScan tubes and analysed on the FACS.

## RESULTS

### 1) Clinical relevance of MAb B5 epitope:

We present data on three paired sera taken from infants early (acute) and later (convalescent) during culture confirmed invasive meningococcal disease (IMD) that resulted from infection with *Neisseria meningitidis* isolates of immunotypes L1, L3 (MAb B5 reactive) (patients 1 and 2) and L2 immunotype (MAb B5 non-reactive) (patient 3) (Figure 10). The *Neisseria meningitidis* isolates for patients 1, 2, 3 were L1 (B nt p1.14), L3 (B15 p1.7) and L2 (C2a p1.5) respectively. One paired sera from patient 2 infected with a *Neisseria meningitidis* strain that was MAb B5 reactive demonstrated an increase in specific inner core LPS antibodies by ELISA between early and late infection ( $p=0.03$  not significant two-tailed paired t-test, 95% CI 0.09-90.8)) (Figure 10a). Patient 1 sera demonstrated no significant difference in the titre of antibody taken early and later during IMD but the titre of the early sample was already at a high level (Figure 10a). The lack of increase may reflect higher affinity antibody in the convalescent sample that would not be detected in this ELISA. However in both patient 1 and 2 sera there was a nearly significant increase in functional activity in the convalescent sera in an opsonophagocytosis assay with L3 wild-type strain MC58 and human peripheral polymorphonuclear cells ( $p=0.06$  two-tailed paired t-test, 95%CI 0.90-5.96) (Figure 10b) (Plested *et al.*, 2000b). There was no significant increase in specific antibody titre between acute and convalescent sera taken from patient 3 infected with L2 immunotype strain (MAb B5 non-reactive) as measured by ELISA (Figure 10a). There was no significant functional activity in OP assay against L3 wild-type strain with sera taken from patient 3 early or later during IMD (Figure 10b). This demonstrates the clinical relevance of the MAb B5 epitope *in vivo* and that specific inner core LPS antibodies are functional *in vivo*.



Figure 10. A. ELISA titres of antibodies to L3 *galE* LPS (IgG) in paired sera taken early and late from children with invasive meningococcal disease.

B. Mean % phagocytosis of *Neisseria meningitidis* MC58 with paired sera taken early and late from children with invasive meningococcal disease with human peripheral blood mononuclear cells and human complement.

## 2) Supporting evidence that murine MAb B5 has functional activity in biologically relevant assays and an *in vivo* model.

### (i) Opsonophagocytosis assay

The OP assay provides evidence that MAb B5 has opsonic activity against *Neisseria meningitidis* wild type and *galE* mutant and that the OP activity is specific for MAb B5 epitope.

The specificity of MAb B5 reactivity using wild-type *Neisseria meningitidis* MC58 was shown by inhibition studies. MAb B5 was pre-incubated with different concentrations of purified LPS. There was a dose response inhibition in OP activity with *Neisseria meningitidis* MC58 with increasing concentrations of *galE* LPS added to MAb B5 (see Figure 11a).

Figure 11a. Mean % phagocytosis of *Neisseria meningitidis* MC58 with MAb B5 pre-incubated with increasing concentrations of either (i) B5 reactive or (ii) B5 non-reactive *galE* LPS with human peripheral blood polymorphonuclear cells and human complement.

MAb B5 has specific OP activity for MAb B5 reactive strains using an isogenic pair of *Neisseria meningitidis* wild-type strains (*Neisseria meningitidis* BZ157, serogroup B) that are MAb B5 reactive or MAb B5 non-reactive. MAb B5 has opsonic activity with MAb B5 reactive strain but not MAb B5 non-reactive strain (see Figure 11b).

Figure 11b. Mean % phagocytosis of pair of *Neisseria meningitidis* wild-type isogenic strains (*Neisseria meningitidis* BZ157) that are either MAb B5 reactive or B5 non-reactive with MAb B5 as the opsonin with human peripheral blood mononuclear cells and human complement.

OP assay demonstrated the uptake of beads coated with purified L3 *galE* LPS opsonised with MAb B5 was significantly greater than the uptake with uncoated beads. This demonstrates the specificity of MAb B5 for *galE* LPS coated onto beads (see Figure 11c).

Figure 11c. Mean % phagocytosis of fluorescent latex beads coated with either purified LPS from L3 *galE* mutant (10µg/ml) or uncoated, in the presence of MAb B5 or final buffer, with human peripheral blood mononuclear cells and human complement.

## (ii) Serum bactericidal assay

The SB assay provides evidence that MAb B5 has bactericidal activity against *Neisseria meningitidis galE* mutant in SB assay in the presence of a human complement source (see method).

The serum sensitivity of *galE* mutant with either no antibody or in the presence of MAb B5 was compared (Figure 12). There was a dose response increase in bactericidal activity of *galE* mutant shown by decreasing % survival, with decreasing % of serum in the presence of MAb B5 compared to no antibody.

Figure 12. Mean % survival of *Neisseria meningitidis galE* mutant in the presence and absence of MAb B5 against two-fold serial dilutions of human pooled serum starting at 40% as detected using a serum bactericidal assay (see methods).

## (iii) Passive protection model using the infant rat.

Using the 5-day-old infant rat model we have demonstrated that two doses MAb B5 are able to reduce bacteremia against challenge with  $1 \times 10^8$  cfu/ml *Neisseria meningitidis* MC58 *galE* mutant i.p. compared to no antibody controls. This data demonstrates the ability of MAb B5 to

passively protect against challenge with *Neisseria meningitidis* MC58 *galE* mutant and correlates with the functional activity of MAb B5 in OP and SB assays against the same *Neisseria meningitidis* strain.

Figure 13. Geometric mean bacteremia in the blood of groups of 5 day old infant rats 24h post-infection with  $1 \times 10^8$  cfu/ml *galE* mutant given simultaneously with either: (i) no antibody (ii) MAb B5 (10 $\mu$ g dose); (iii) MAb B5 (100 $\mu$ g dose); (iv) MAb 735, a positive control anti-capsular antibody (2 $\mu$ g dose).

#### **MAb B5 binding studies**

Additional evidence that MAb B5 recognises both wild-type and *galE* mutant LPS is shown in the following binding studies:

##### **a) Western blot analysis**

Purified LPS from wild type *Neisseria meningitidis* MC58 and *galE* mutant was separated on standard Tricine gel and blotted onto nitrocellulose by standard methods. The blot was probed with MAb B5 culture ascites (1:2000) overnight and detected using anti-mouse IgG and BCIP/NBT substrate. The blot demonstrates binding of MAb B5 to higher molecular weight wild-type LPS band and lower molecular weight *galE* LPS band in wild-type LPS. This demonstrates that MAb B5 can access and bind to the wild-type LPS as well as truncated *galE* LPS.

Figure 14. Western blot showing purified LPS from *Neisseria meningitidis* MC58 and *galE* mutant probed with MAb B5 (ascites fluid 1:2000) detected using anti-mouse IgG alkaline phosphatase and BCIP/NBT substrate.

##### **b) FACS surface labelling data**

MAb B5 binding to live wild-type strain MC58 and *galE* mutant ( $1 \times 10^8$  cfu/ml) were quantitatively compared using surface labelling with anti-mouse FITC and analysed by FACS.

Figure 15. FACS profile comparing surface labelling of live *Neisseria meningitidis* MC58 and *galE* mutant ( $5 \times 10^8$  org./ml) with MAb B5 (culture supernatant 1:50) detected using anti-mouse IgG (FITC labelled).

**Claims**

1. A vaccine for the treatment of disease caused by pathogenic *Neisseria*, the vaccine comprising an immunogenic component based on the inner core of a *Neisseria* lipopolysaccharide, LPS, and being capable of eliciting functional antibodies against a majority of the strains within the species of the pathogenic *Neisseria*.
2. A vaccine according to claim 1, wherein the said immunogenic component is capable of eliciting functional antibodies against at least 60% of the strains within the species of the pathogenic *Neisseria*.
3. A vaccine according to claim 2, wherein the said immunogenic component is capable of eliciting functional antibodies against at least 70% of the strains within the species of the pathogenic *Neisseria*.
4. A vaccine according to any preceding claim, wherein the immunogenic component is substantially free from outer core lipopolysaccharide.
5. A vaccine according to any preceding claim, wherein the species of the pathogenic *Neisseria* is *Neisseria meningitidis*.
6. A vaccine according to claim 5, wherein the antibodies are elicited by the immunogenic component in at least 50 % of group B strains of *Neisseria meningitidis*.
7. A vaccine according to claim 5, wherein the antibodies are elicited by the immunogenic component in at least 60% of group B strains of *Neisseria meningitidis*.
8. A vaccine according to claim 5, wherein the antibodies are elicited by the immunogenic component in at least 70% of group B strains of *Neisseria meningitidis*.

where R1 is a substituent at the 3-position of HepII, and is hydrogen or Glc- $\alpha$ -(1, or phosphoethanolamine; R2 is a substituent at the 6-position of HepII, and is hydrogen or phosphoethanolamine; R3 is a substituent at the 7-position of HepII, and is hydrogen or

14. A vaccine according to any preceding claim, wherein the immunogenic component is reactive with the B5 antibody produced by the hybridoma deposited under accession number IDAC 260900-1.
15. A vaccine comprising a few immunogenic components based on the inner core of a *Neisseria* lipopolysaccharide, LPS, and being capable of eliciting functional antibodies against a majority of the strains within the species of the pathogenic *Neisseria*.
16. A vaccine according to claim 15 and including an immunogenic component as defined in any of claims 1 to 14.
17. A vaccine according to claim 15 or 16, wherein the said few immunogenic components elicit functional antibodies in at least 85% of the strains within the species of the pathogenic *Neisseria*.
18. A vaccine according to claim 17, wherein the said few immunogenic components elicit functional antibodies in at least 95% of the strains within the species of the pathogenic *Neisseria*.
19. A vaccine according to any of claims 15 to 18, wherein an immunogenic component is reactive with the A4 antibody produced by the hybridoma deposited under accession number IDAC 260900-2.
20. A vaccine according to any preceding claim, wherein the immunogenic element of the vaccine is an epitope accessible on the bacterium in the presence of bacterial capsule.

21. A vaccine according to any preceding claim, comprising one or more immunogen components which are capable of stimulating antibodies which are opsonic.
22. A vaccine according to any preceding claim for the treatment of *Neisseria meningitidis*.
23. A vaccine according to claim 22 for the treatment of *Neisseria meningitidis* group B.
24. A vaccine according to any preceding claim for the prevention of meningitis, septicaemia or pneumonia or other manifestation of systemic or local disease occasioned by *Neisseria meningitidis*.
25. A vaccine according to any of claims 1 to 22 for the treatment of urethritis, salpingitis, cervicitis, proctitis, pharyngitis, pelvic inflammatory disease or other manifestation of systemic or local disease occasioned by *Neisseria gonorrhoeae*.
26. A vaccine according to any preceding claim which is a conjugated vaccine.
27. A vaccine according to any preceding claim, which is derived from a commensal *Neisseria*.
28. A vaccine according to claim 27, wherein the commensal *Neisseria* is *Neisseria lactamica*.
29. An antibody reactive with an immunogenic component as defined in any preceding claim.
30. An antibody according to claim 29, wherein the antibody is humanized or otherwise customised to enhance suitability for administration to a human.
31. An antibody according to claim 29, obtainable from the hybridoma producing antibody B5.



32. An antibody according to claim 29, obtainable from the hybridoma producing antibody A4.
33. A hybridoma producing antibody B5.
34. A hybridoma producing antibody A4.
35. A pharmaceutical preparation comprising an antibody according to any of claims 29 to 32 in combination with a pharmaceutically acceptable carrier.
36. A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of a vaccine according to any of claim 1 to 28.
37. A method for the treatment of *Neisseria* infection, the method comprising administering to a subject in need of such treatment an effective amount of an antibody according to any of claims 28 to 31.
38. A method for the identification of immunogenic epitopes of strains of a species of *Neisseria*, the method comprising the steps of generating antibodies to the inner core of a *Neisseria* bacterium, by inoculation of a host organism with a *galE* mutant strain of *Neisseria meningitidis*, and testing such antibodies against a wild type *Neisseria meningitidis* strain to identify those antibodies which are reactive, and for which the epitopes are therefore accessible.
39. Use of one or more biosynthetic pathway genes in the production of a *Neisseria* strain for the assessment, treatment or prevention of *Neisseria* infection.
40. Use of an immunogenic component, or a few immunogenic components, based on the inner core of a *Neisseria* lipopolysaccharide, LPS, and being capable of eliciting

functional antibodies against a majority of the strains within the species of the pathogenic *Neisseria*, in the preparation of a medicament for the treatment of a disease caused by a pathogenic *Neisseria* infection.

41. Use of an antibody according to any of claims 29 to 32 in the preparation of a medicament for the treatment of *Neisseria* infection.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/22994 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/095**,  
39/40, A61P 31/04

(21) International Application Number: PCT/GB00/03758

(22) International Filing Date: 2 October 2000 (02.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/156,940 30 September 1999 (30.09.1999) US  
60/196,305 12 April 2000 (12.04.2000) US

(71) Applicant (for all designated States except US): **ISIS INNOVATION LIMITED** [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford, Oxfordshire OX2 7BZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PLESTED, Joyce**, S. [GB/GB]; Department of Clinical Immunology, Churchill Hospital, Headington, Oxford OX3 7LJ (GB). **JENNINGS, Michael, P.** [AU/AU]; Department of Microbiology, University of Queensland, St. Lucia, Brisbane, QLD 4072 (AU). **GIDNEY, Margaret, Ann, J.** [CA/CA]; Institute for Biological Sciences, National Research Council, Ottawa K1A 0R6 (CA). **COX, Andrew, D.** [GB/CA]; Institute for Biological Sciences, National Research Council, Ottawa K1A 0R6 (CA). **RICHARDS, James**,

C. [CA/CA]; Institute for Biological Sciences, National Research Council, Ottawa K1A 0R6 (CA). **MOXON, E., Richard** [GB/GB]; Molecular Infectious Disease Group, Oxford University Department of Paediatrics, John Radcliffe Hospital, Oxford OX3 9DU (GB).

(74) Agent: **RUFFLES, Graham, Keith**; Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: VACCINE

(57) Abstract: The invention relates to a vaccine for the treatment of disease caused by *Neisseria*, the vaccine comprising one or more immunogenic components for *Neisseria* serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating *Neisseria* infections. The immunogens are based on elements of the inner core lipopolysaccharide.

WO 01/22994 A2



2/15



*N.meningitidis* LPS

Fig. 2





Fig. 3



4/15




Fig. 4

5/15




Fig. 5



6/15




Fig. 6

7/15




Fig. 7

8/15




Fig. 8

9/15

STRATEGY DIAGRAM  
(Methods used in brackets)

↓  
Identify antibody  
accessible epitopes of  
wild-type encapsulated  
Gp B Nm strains  
(2,3,4)

↓  
Investigate conservation  
of antibody accessible  
inner core epitopes in  
natural population of Nm  
(3)

↓  
Investigate the structure  
of LPS derived from Nm  
of known mab reactivity  
(5)

↓  
Define details of  
conserved antibody  
accessible epitopes  
(2,5)

↓  
Select minimum number  
of glycoforms having  
range of epitopes  
representative of all Nm  
strains  
(3,4,5)

↓  
Investigate potential of  
glycoform to elicit  
functional antibodies  
(e.g bacterial,  
opsonophagocytic &  
animal protection  
assays)

Fig. 9

10/15




Fig. 10a





Fig. 10b

WO 01/22994

PCT/GB00/03758



B5+ galE LPS  
B5- galE LPS

Fig. 11a




Fig. 11b




Fig. 11c

12/15




Fig. 12

13/15




Fig. 13



14/15




Fig. 14

15/15




Fig. 15

**COMBINED DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled VACCINE, the specification of which:

- ☐ is attached hereto.  
☐ was filed on \_ as Application Serial No. \_ and was amended on \_\_\_\_\_.  
☒ was described and claimed in PCT International Application No. PCT/GB00/03758 filed on 2 October 2000 and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

<u>U.S. Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
60/156,940	September 30, 1999	
60/196,305	April 12, 2000	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>U.S. Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/GB00/03758	October 2, 2000	Pending

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Priority Claimed</u>
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Timothy A. French, Reg. No. 30,175  
 David L. Feigenbaum, Reg. No. 30,378

William E. Booth, Reg. No. 28,933  
 John F. Hayden, Reg. No. 37,640

(4)

2/05/02 12:58 FAX NO.: 01865 221889

PROF RICHARD MOKON

P. 886

Attorney's Docket No.: 11560-003US1  
Client's Ref. No.: F/USP82704**Combined Declaration and Power of Attorney**  
Page 2 of 3 PagesAddress all telephone calls to **TIMOTHY A. FRENCH** at telephone number (617) 542-5070.Address all correspondence to **TIMOTHY A. FRENCH** at:**FISH & RICHARDSON P.C.**  
**225 Franklin Street**  
**Boston, Massachusetts 02110-2804**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

1-00 Full Name of Inventor: **JOYCE S. PLESTED**Inventor's Signature: Joyce S. PlestedDate: 29/5/02

Residence Address:

Citizenship:

Post Office Address:

British

Department of Clinical Immunology

Churchill Hospital

Headington

Oxford OX3 7LJ

UNITED KINGDOM

Oxford University  
Department of Paediatrics  
John Radcliffe Hospital  
Oxford OX3 9DU GBX  
United Kingdom2-00 Full Name of Inventor: **MICHAEL P. JENNINGS**Inventor's Signature: M. JenningsDate: 23/5/02

Residence Address:

Citizenship:

Post Office Address:

St. Lucia, Brisbane QLD

Australian

Department of Microbiology

University of Queensland

St. Lucia

Brisbane QLD 4072

AUSTRALIA

AUX

Combined Declaration and Power of Attorney  
Page 3 of 3 Pages

3-00 Full Name of Inventor: MARGARET ANNE GIDNEY

Inventor's Signature: M. A. Gidney  
Residence Address: National Research Council, Ottawa  
Citizenship: Canadian  
Post Office Address: Institute for Biological Sciences  
National Research Council  
Ottawa K1A 0R6  
Canada CAX

Date: 22 May 2002

4-00 Full Name of Inventor: ANDREW D. COX

Inventor's Signature: Andrew D. Cox  
Residence Address: National Research Council, Ottawa  
Citizenship: British  
Post Office Address: Institute for Biological Sciences  
National Research Council  
Ottawa K1A 0R6  
Canada CAX

Date: 23<sup>rd</sup> May 2002

5-00 Full Name of Inventor: JAMES C. RICHARDS

Inventor's Signature: James C. Richards  
Residence Address: National Research Council, Ottawa  
Citizenship: Canadian  
Post Office Address: Institute for Biological Sciences  
National Research Council  
Ottawa K1A 0R6  
Canada CAX

Date: 22 May 2002

6-00 Full Name of Inventor: E. RICHARD MOXON

Inventor's Signature: E. Richard Moxon  
Residence Address: British  
Citizenship: Molecular Infectious Disease Group  
Post Office Address: Oxford University Department of Paediatrics,  
John Radcliffe Hospital  
Oxford OX3 9DU  
United Kingdom GBX

Date: 29/05/02

20411881.doc

Attorney's Docket No.: 11560-003US1  
Client's Ref. No.: F/USP82704

**Combined Declaration and Power of Attorney**  
Page 2 of 3 Pages

Address all telephone calls to TIMOTHY A. FRENCH at telephone number (617) 542-5070.

Address all correspondence to TIMOTHY A. FRENCH at:


**FISH & RICHARDSON P.C.**  
225 Franklin Street  
Boston, Massachusetts 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: **JOYCE S. PLESTED**

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Residence Address: \_\_\_\_\_  
Citizenship: **British**  
Post Office Address: **Department of Clinical Immunology  
Churchill Hospital  
Headington  
Oxford OX3 7LJ  
UNITED KINGDOM**

Full Name of Inventor: **MICHAEL P. JENNINGS**

Inventor's Signature:  \_\_\_\_\_ Date: **23/5/02**  
Residence Address: ~~St. Lucia, Brisbane QLD~~  
Citizenship: **Australian**  
Post Office Address: **Department of Microbiology  
University of Queensland  
St. Lucia  
Brisbane QLD 4072  
AUSTRALIA**

